Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
#2/ The Army's CODE NAME XM25 with 'smart' bullets
szalinski
szalinski
THEFIIFTHELEMNET
Uploaded on Dec 2, 2010
How long before the Zorg ZF-1 is developed?
And even worse, what if it falls into the wrong hands?
Taken from The Global Reality with Josh Reeves on 12/1/10
http://www.theglobalreality.com
http://www.leesgreatwork.com
Category
Science & Technology
License
Standard YouTube License
#1/ PACIFIC PIVOT BY U.S.A. SECURITY/ MACH 7 CANNON
#1/ PACIFIC PIVOT BY U.S.A. SECURITY/ MACH 7 CANNON
http://pro.moneymappress.com/EADMCE37/EEADT1CP/?email=rbalc%40yahoo.com&a=8&o=31232&s=45594&u=408658&l=1054605&r=MC2&vid=-TG6e0&g=0&h=true
SECURITY/
ASSASSIN MACE
U.S.A. SUPER WEAPON/ MACH 7 CANNON
SMART BULLETS/ DR.WILLIAM ROGERS
SUPER WEAPONS/SMART BULLETS
CHIEF NAVAL RESEARCH
TO DESTROY U.S.A. NAVY
AEGIS COMBAT SYSTEM
CHINA DF21 MISSILES
https://pro.moneymappress.com/p/EADMCE37/EEADT2AD/?email=rbalc%40yahoo.com&a=8&o=32412&s=47378&u=408658&l=1089374&r=MC2&vid=rNY_9A&g=53&h=true
LIQUID CRYSTALS , NANO-DOTS --- IMPORTANT STUFF
JASON STUTMAN
HTTP://WWW.WEALTHDAILY.COM
HTTP://WWW.MONEYSHOW.COM
liquid crystal energy/ LCE is a "universal fuel." It can be used for everything.
It can light and heat your home...
Run factories...
Propel space ships...
It can even power the ENTIRE U.S. electrical grid...
http://www.angelnexus.com/o/web/120616
science
http://www.alliedmarketresearch.com
PSMH Wallstreet Giant Michael Margolies holds 82% of the Commons.
This guy is a serious investor!!
Coal is NOT Dead!/ Cloud Peak Energy (NYSE: CLD
Westmoreland Coal Company (NASDAQ: WLB)
http://www.energyandcapital.com/editors/jeff-siegel
http://www.energyandcapital.com/resources
http://www.energyandcapital.com/
ghost town ????? seems like da spirits dare. This Will Be Like Investing in the Smartphone in 2009
[-chart]www.moneymappress.com/pro/images/0117MMPDrones/I_01b.png[/chart]
[-chart]www.moneymappress.com/pro/images/0117MMPDrones/I_01.png[/chart]
[-chart]www.moneymappress.com/pro/images/0117MMPDrones/I_01a.png[/chart]
They Call Their Ghost Town "Project CITE"
It's the brainchild of the government contractor Marble Arch.
And when you learn how tight Marble Arch is with the Pentagon and how many massive government contracts Marble Arch has scooped up over the years, you know something big is happening here.
Marble Arch is run by Bob Brumley, who was President Reagan's point man for privatizing commercial space transportation. He's definitely a big thinker – like an Elon Musk with a direct line to government funding!
And this new venture of his is every bit as ambitious as space travel, with even bigger impact, because it's going to happen right before our eyes.
Now, as I mentioned, the specific details of this venture are not public. But after my investigation, I'm incredibly confident it will involve the next big thing in tech, security, and investing.
I'm talking about unmanned flying machines.
Yes, drones.
A.I. DRONES
[-chart]www.moneymappress.com/pro/images/0117MMPDrones/I_04.png[/chart]
just months away from seeing millions of these new A.I. Drones flying down every highway, street and alley, field, and mountain in America.
If you've thought of drones in military terms or just as toys, this is a wake-up call. Because we're about to see seven million drones of all kinds taking flight.
Yes, seven million, and this figure is not mine. It's from the FAA Administrator, Michael Huerta. He knows what's in the pipeline – he has to.
Seven million drones of all kinds. That's one massive explosion of drones. It works out to one drone in every two square miles overhead!
You're going to be seeing one just about every time you look up.
And not just in the States. Here are the worldwide projections that matter to investors – projections from the predictive analytics authority Tractica:
every industry would benefit from acquiring and deploying fleets of new drones…
In agriculture, there are 2.1 million farms that can be better mapped and managed with smarter drones – so that's on the radar.
Phone companies have 215,000 cell towers they need 100% operational. It could be done safer, faster, and cheaper using these new drones.
Some 49,000 wind turbines need regular inspecting. Drones could do it more efficiently and more safely than having humans scaling the towers. So you know what that means for drone orders.
Railroads have 140,000 miles of aging track that need constant inspecting for the tiny cracks that cause derailments. These new drones could do it in a snap.
In worse shape still are America's 600,000 bridges: 65,000 of them have been labeled "dangerous" and require 24/7 monitoring – so these new drones are the perfect solution.
Technically this loophole was called the Section 107.200 Certificate of Waiver – and it means that for the first time ever, companies will be allowed to:
Fly these new drones legally for thousands of different operations…
Do it even without a pilot's license – just pass a basic knowledge test…
And most critically, request to operate them far beyond "line of sight" which was not allowed before.
[-chart]www.moneymappress.com/pro/images/0117MMPDrones/I_11.png[/chart]
drone market – which makes it the dominant player and puts it way ahead of any newcomers.
I think of it as a pioneer…
"Pioneer" because it also supplies the military – in fact, it is the Pentagon's largest supplier of small drones, and 19 countries buy from it, as well.
The military A.I. Drones pioneered by this company follow in the footsteps of the greatest technology ever created.
Think about computers… microwaves… GPS systems…
These paradigm-shifting technologies all began as military inventions that eventually found massive success in the civilian world.
Tiny A.I. Drone Company ?????
boasts a body like an airplane, rotors like a helicopter, and takes off like a rocket.
This little workhorse is so fast it can outrun a car and cover 40 full miles without recharging.
Every Industry on the Planet Wants These Smart A.I. Drones...
Starting with the $985 billion agriculture industry in the U.S. otherwise known as Big Ag…
The many uses for our company's A.I Drones in the global farming industry become quickly obvious.
[-chart]www.moneymappress.com/pro/images/0117MMPDrones/I_13.png[/chart]
With the ability to survey 400 acres of farmland in 45 minutes, these A.I. Drones can give farmers precise readings on the health of crops – whether the watering is right, whether they're free of insects and disease.
Ferguson + Orlando + Dallas = More Drone Deployments
We've all seen what's happening in American cities.
It's becoming unsafe for police officers to enter certain neighborhoods of Ferguson, Baltimore, Los Angeles, Oakland, Detroit, Dallas, and so on…
[-chart]www.moneymappress.com/pro/images/0117MMPDrones/I_14.png[/chart]
Report #1: The Pentagon's Secret War Plan
#2: Driverless Cars – The Surprises Ahead
A.I. Drones: The Next Frontier In Flight...
The Pentagon's Secret War Plan
DRIVING FOR DOLLARS: Ways to Autonomous Cars.
http://pro.moneymappress.com/MMPDRN39/EMMPT203/?email=rbalc%40yahoo.com&src=d2&a=8&o=31918&s=46612&u=408658&l=1074328&r=MC2&vid=vJzH8v&g=0&h=true
$PMCB Cell-in-a-Box® Technology Platform offering hope in the treatment of Pancreatic Cancer, Breast Cancer, Malignant Ascites Fluid and Diabetes PMCB
PharmaCyte (OTCQU:PMCB)
www.pharmacyte.com
Interview conducted by:
Bud Wayne, Editorial Executive, CEOCFO Magazine, Published - September 5, 2016
CEOCFO: Mr. Waggoner, would you tell us about how you came to be with PharmaCyte and how long you have been with the company?
Mr. Waggoner: I was working for a startup company when one of the Board members of the Company, known then as Nuvilex, asked me to join the Company to reorganize it and advance its technology in the field of cancer and diabetes. At the time, it was a nutraceutical company that was trying to change into a pure biotech play. He knew my background in business and law well and that the job required both skill sets. He called in January of 2012 the first time. I was engaged fulfilling an obligation to another startup company and passed on this opportunity at that time. Every-six-months he would call. In August of 2013 he made a final plea. It just happened to be a time when I had decided to go back into the practice of law for a major law firm. This time, I looked closely at the technology that he had been so excited about on every call. At that time, the Company had a platform technology for the treatment of cancer and diabetes, but the technology was not being advanced. After looking at the technology more carefully, I ran it by one of my former law partners who also runs a biotech company. He said that if the technology proves to be what it appears to be, this could make medical history and that I should join the Company, because of my background in management and law. I came on board in September of 2013 as a consultant, and then in late 2013 took over as CEO and President. Not long thereafter, I took on the responsibility of being General Counsel as well.
CEOCFO: Would you tell us about your role as CEO?
Mr. Waggoner: It is a defined role. I am CEO, president and general counsel. I establish the goals and strategies for the Company. Together with Dr. Gerald W. Crabtree, we implement them with help from professional colleagues who work with us as consultants and as part of our management team. We have orchestrated what has become a worldwide organization with some of the best and brightest physicians and scientists around the globe. We took a relatively small company and have achieved some rather remarkable things with it in a very brief period for a biotech company. We are poised to inaugurate our platform technology in the U.S. and Europe in the field of cancer. We call the platform technology, “Cell-in-a-Box®.” We are about to introduce it to the United States the very first time. The technology was actively being developed in the late 1990s through the mid-2000s. It was picked up by the Company in early 2011, but not much happened between then and when I joined the Company.
CEOCFO: Dr. Crabtree, would you tell us about your role and how long you have been with PharmaCyte?
Dr. Crabtree: I have been in the cancer drug development and treatment development area, since graduate school back in the late 1960s. I have been around the block a few times. I spent fifteen years at Brown University on the faculty there. About half the time at Brown I spent most of my time in Roger Williams Cancer Center, which was associated with Brown University. I was fortunate to be working with one of the best oncologists of that time. We developed several drugs to early stages of development. We did early clinical trials on several of them. One of these agents ultimately became a fully functional drug in terms of sales for a well-known pharmaceutical company. Following that, I spent six years in southern California running the Department of Molecular Pharmacology for ICN Pharmaceuticals, Inc., where we examined the anti-tumor and anti-viral activity of a variety of compounds that were produced by the company’s medicinal chemists. Then in 1990, I was recruited by Bristol-Myers Squibb to establish a department of Project Planning and Management for oncology and immunology. Personally, I was tasked with coordinating the development of three different drugs. By far the most important of these was a drug called Taxol®, which is pretty well known in the cancer business. It was recognized as the most important cancer drug developed during the 1990s and it ultimately made Bristol-Myers Squibb $15-17 billion, I believe. Following that, I left Bristol-Myers Squibb in 1996 or early 1997 and did a lot of consulting with various biotech companies and helped them in the project management area to develop their products. In the year 2000, I joined a biotech company in Cambridge, Massachusetts called ETEX Corporation as VP of R&D for the oncology part of their company. ETEX was actually a medical device company that wanted to use their main product, which was a form of calcium phosphate, as a depot to enable the controlled release of cancer drugs. That was very popular area for study at that time. When I left there in about 2005, I consulted with another biotech company that was working on a traditional Chinese medicine formulation to assist in the chemotherapy of colorectal cancer initially. Later, that same formulation was used in trials for primary liver cancer as well as pancreatic cancer. I joined what was then Nuvilex in 2011. When I first joined, we had not yet acquired the Cell-in-a-Box technology that Ken mentioned earlier. We soon did acquire it, and I have been with the Company ever since. This technology is so different from anything else that I have been exposed to in the cancer field and I have heard the same thing from a lot of prominent oncologists. The use of the Cell-in-a-Box encapsulation technology together with a cancer prodrug is a brand-new way to look at the treatment of solid tumors. Solid tumors are the tough ones to treat. For leukemias, we have treatments, some of which are very good, but solid tumors are still a problem. The reason is that it is hard to get a high enough concentration of an effective drug to the tumor so that it will destroy the tumor cells and not have side-effects that make its use impossible.
CEOCFO: Why is Cell-in-a-Box so exciting and what is different from what they have been trying to do with cancer? Is this an adjuvant where you will be using it with other cancer drugs or is this a standalone product that could knock out a solid tumor?
Mr. Waggoner: Cell-in-a-Box is a platform technology we are using for the treatment of cancer and diabetes. We encapsulate genetically modified live cells in small capsules, to treat diseases, which in our case is diabetes and cancer. What we do for cancer is encapsulate live human genetically engineered cells that are capable of converting an inactive chemotherapy drug, or more accurately a prodrug, from its inactive form to its cancer-killing form. In our case, for use against pancreatic cancer, this prodrug is ifosfamide, which is normally activated in the liver. What we do is first encapsulate these prodrug-activating cells and then implant the capsules containing the cells as near to the site of the tumor as possible. Once that is done, we give the patient low doses of ifosfamide intravenously. As the ifosfamide is carried by the blood to where these capsules are sitting near the tumor, it then enters the capsules through slits or pores that allow nutrients and oxygen to enter the capsules and feed the cells inside them. Ifosfamide enters the capsules through these slits as well. When it does, the ifosfamide is converted from its inactive form to its active form. It’s as though you have an artificial liver right at the site of the tumor. We get optimal cancer cell-killing effect because the concentration of the active form of ifosfamide is at its highest as it leaves the capsules. That’s remarkable. But what makes it even better is that our treatment results in no treatment-related side effects. For diabetes, we use the same Cell-in-a-Box live cell encapsulation technology, but with a different cell line. For diabetes, we encapsulate cells that have been genetically modified to read your blood glucose levels, produce insulin, store it and then release the insulin when needed by person with diabetes. This cell line was developed by a Professor Ann Simpson and her colleagues at the University of Technology Sydney in Australia. The cells are called Melligen. We plan to encapsulated Melligen cells and implant them in the body to act as a type of bio-artificial pancreas for producing insulin. There is a lot more to what we do, but I think we are best served by talking more about our cancer program because that is the area that is most advanced and is the one that is close to entering into the clinic here in the U.S. and Europe. Gerry will talk about the mechanisms of action and how unique this is from any other way of treating solid tumors, as well as the potential it has for changing the way solid tumors are treated forever.
CEOCFO: Will you also tell us what causes the cell death in the cancer?
Dr. Crabtree: Let me take a step back. One of the big things that people in cancer treatment have tried to do for many years is develop what are known as targeted therapies for specific solid tumors. All types of cancer are not the same and they all have to be treated differently. There are certain cases where targeted chemotherapies have been developed. A prime example of that is a drug called Herceptin® that was originally developed by Genentech, but is now owned by Roche. Herceptin is directed to a specific population of cells in breast cancer patients with genetically inherited disease; not in all breast cancer patients, but in about 20-25% of them. This drug is so target-oriented that it goes to those cancer cells that have increased ability to react to Herceptin, binds to them and stops their growth. That is an example of targeted chemotherapy. I look at this chemotherapy that we have that uses Cell-in-a-Box, as being a targeted chemotherapy as well. The difference is that what we are doing is planting a target very close to the tumor and then a prodrug is given that hits that target and then this prodrug is activated or converted into its cancer-killing form right near the tumor. The drug we use in our pancreatic cancer work is ifosfamide, an old drug that has been around for a long time, and it has been widely used for different cancers. It is, by itself, active against pancreatic cancer; however, the doses that you need to give to get any positive anticancer activity are so high that very serious and even deadly side-effects can occur. Again, what we at PharmaCyte do is take Cell-in-a-Box capsules that contain cells that are genetically engineered to contain an enzyme that converts the ifosfamide into its cancer-killing form. During this conversion, ifosfamide is metabolized into two different substances and one of them is the cancer-killing form of the drug. If you had cancer cells in a Petri dish and you put ifosfamide in there by itself, probably nothing would happen. The cancer cells would just grow happily and reproduce. What we are doing really is setting up a little ifosfamide-activation factory very close to the site of the tumor itself. Once the ifosfamide prodrug gets into the Cell-in-a-Box capsules, it is converted into the active form of this drug which then kills the cells of the pancreatic cancer. This is an amazing thing to me because I have never seen anything like it. The whole premise is different from what normal cancer chemotherapeutic people like me have been used to. We are used to searching for and discovering drugs from all different sources or making drugs and testing them and trying to find something that is effective against the tumor and does not kill the patient. This way, because we are putting an artificial liver or a little ifosfamide activation factory right next to the tumor, we are able to use a low concentration of the cancer drug, essentially one-third of the normal dose of ifosfamide, when we give the drug after the capsules are implanted. This is enough to kill a significant percentage of the cancer cells in the pancreatic cancer. That is the advantage of this technology as I see it. However, its use is not limited to pancreatic cancer. We could use it for other types of solid tumors. In fact, we have preclinical data from a study of breast cancer in dogs, but we do not use Ifosfamide in this case. We use the exact same capsules with the exact same cells inside them as for pancreatic cancer, but here we use a different drug called cyclophosphamide. This drug is well known and used in a variety of combination chemotherapies for breast cancer. It is a sister drug to ifosfamide. Like ifosfamide, it is inactive in its own right and must be activated. Normally, as for ifosfamide, that activation occurs in the liver but in our case we are putting the activation factory close to the tumor. In the clinical dog study, these were dogs that had spontaneously occurring mammary tumors so they are a perfect model for human breast cancer. What we did in this case was implant groups of the Cell-in-a-Box capsules at several locations around the tumor itself and then gave cyclophosphamide and got remarkable anti-tumor effects.
CEOCFO: You also mentioned diabetes, how does this Cell-in-a-Box relate in trying to treat or cure diabetes?
Dr. Crabtree: For diabetes, we use the same Cell-in-a-Box encapsulation process. The difference is the cell type that we are encapsulating. These capsules are perfect spheres. They are about 0.7 millimeters in diameter. They are not microscopic, but they are quite small. Each capsule, in the case of pancreatic cancer, holds about 10 thousand cells. In the case of diabetes, we are using a totally different cell line that was developed in Australia. The cell line is a genetically altered form of a human liver cell. This cell line is called Melligen and has been designed to produce, store, and release insulin on demand. For people that have Type I diabetes, their pancreas cannot produce insulin because the insulin-producing cells have been destroyed by the individual’s own immune system. Insulin is only produced in the pancreas under normal conditions. Insulin helps the glucose in the blood get from the blood fluid to the inside of cells in the body. It helps the glucose cross cell membranes to get inside the cells. You want that because glucose is a major source of energy for most types of cells in the body. With type II diabetics, of whom I am one, the pancreas can produce insulin but usually not enough of it to control the blood glucose level. If Type II diabetes is caught early enough, you can control it by diet and exercise. Then later it evolves to where you can control it by anti-diabetes medications and that is where I am now. Eventually these two ways of controlling blood glucose levels are no longer effective and the only treatment for Type II diabetes then is insulin injections by needle or pumps or insulin pens. That is what happens with Type I diabetics all of their lives every day. Their lives are a mess because they have to worry about constantly monitoring their diets and blood glucose levels otherwise their diabetes can kill them. Diabetes is notorious for four areas of damage. These areas are damage to the eyes, known as retinopathy and I have lost partial sight in one of my eyes because of it, then another common result of diabetes is what is called peripheral neuropathy that causes severe pain in the feet and I have that as well. Neuropathy can ultimately result in limb amputations. Diabetes can also affect the cardiac system and one can die from a heart attack and it can also destroy kidney function.
CEOCFO: Is your therapy something that they would do and it would change the whole thing or is it a therapy like the insulin which would need to be taken on a regular basis?
Mr. Waggoner: Again, we have a platform technology called Cell-in-a-Box, and it can also be used in treatment of diabetes. We have the exclusive worldwide license to the cell line that Dr. Crabtree mentioned, called Melligen. We plan to encapsulate those cells and then implant them in a diabetic patient to produce, store and release insulin when needed. We already know that when these cells were implanted into diabetic mice with deficient immune systems, the animals’ diabetic condition was reversed. A peer-reviewed scientific paper published several months ago on the Melligen cells and their ability to reverse the diabetic condition provides the particulars. Again, our plan is to encapsulate the Melligen cells using the Cell-in-a-Box technology and then implant them in the body to act as a type of bio-artificial pancreas for use against Type I diabetes, and as Gerry is, insulin dependent Type II diabetes. Anybody who needs insulin, whether the person has Type I or insulin-dependent Type II diabetes, could have their problem solved if our therapy works as planned. We do not know how long the encapsulated cells will remain in the capsules without the capsules breaking down. But, we know from earlier studies in humans with pancreatic cancer that the capsules do not break down for at least two years; this was for the entire life of some patients in the earlier clinical trials in pancreatic cancer. But until further studies are completed, we won’t know exactly how long they will stay in a body before they have to be replaced. The concept of using the Cell-in-a-Box technology with insulin-producing cells has already been proven successful in an earlier preclinical study using diabetic rats. It was a preclinical proof of principle study of the production and use of a stable bio-artificial pancreas by using these Cell-in-a-Box capsules. What happened in that study was that pig pancreatic islet cells, which are insulin-producing cells, were encapsulated and then placed in diabetic rats. As soon as the capsules with the insulin-producing cells were implanted in the diabetic rats, their blood glucose levels normalized and remained normal throughout the study period of about six months. The long-term protective capability of Cell-in-a-Box capsules was shown for the duration of the study. The live cells inside them could not be damaged by the body’s immune system. So that is how we plan to use the Cell-in-a-Box technology for diabetes. You mentioned how diabetes is a serious disease. In our view it is the number-one health problem in the world. It is an epidemic globally, because 422 million people have diabetes, which is 314 million more than in 1980. Approximately 8.5% of adults worldwide have the disease. More than $920 billion annually is spent treating diabetes and the health related affects that are caused by diabetes. About 10% of every healthcare dollar in the world is spent on diabetes or related healthcare. Just here in the U.S. we have over 30 million people with diabetes. Annually, $600 million is spent just on the treatment of diabetes alone.
CEOCFO: Would you tell us about the Diabetes Consortium?
Mr. Waggoner: Gerry and I went to Europe when we joined forces and began to move the technology forward. We went to Europe in April of 2014. We planned to go for a week and I stayed for six. We got to know some of the most incredible physicians and scientists working in both pancreatic cancer and in diabetes, particularly the latter. I asked Gerry after having met them, why are these people not working together to address the number one healthcare problem around the globe? Gerry said because they are in these world renowned academic institutions and people like that often do not work together but rather compete with each other. I said that it seemed to me that instead of working in their silos, we should come up with a way for all of these incredible people who are trying to find an effective therapy for Type I and insulin-dependent Type II diabetes to work together collaboratively. I suggested to Gerry that we put together a Diabetes Consortium and have the members collaborate in their efforts to accelerate efforts to find an effective therapy for diabetes. Gerry said it would be great, but was skeptical about the practicalities of putting such a consortium together. Feeling fairly certain we could persuade those with whom we met to join our group, we circled back with all these amazing people and shared our vision. That vision then led to the formation of the Company’s international Diabetes Consortium. Some of the scientists were reluctant to join at first, but now they have. We have nineteen members in the Consortium working collaboratively on multiple research tracks; all of this is coordinated by our Director of Diabetes Program Development, Dr. Eva-Maria Brandtner.
CEOCFO: In closing, will you tell us where you are with financing and will you be looking for partners?
Mr. Waggoner: I did a shareholder call on the 28th of July that can be listened to by anyone interested in where we are with financing. It is the most current update on the state of our affairs as of the 28th of July. We recently filed our annual report on Form 10K. There you will find as much detail as you can possibly imagine about the company. We are always looking for opportunities to finance the activities in which we are engaged. We are in discussions with pharmaceutical companies around the globe. We have financial partners that are helping us fund our activities. Until recently we were using a shelf registration vehicle to fund a lot of our activities. But we are always considering funding opportunities, including grants, partnerships, joint ventures, private placements and so forth.
Dr. Crabtree: I first would like to say a few words on pancreatic cancer. We are not doing the pancreatic cancer work in a vacuum. We are working with three of the leading pancreatic cancer specialists in the world on our program. They approached us; we did not approach them. This is particularly true in the case of an oncologist named Dr. Daniel D. Von Hoff. He is, to my mind, the world’s leading authority in pancreatic cancer. He approached us to get involved with our program. What we are going to do over the next few months is go to the FDA and then start a Phase 2b clinical trial in patients with locally advanced, inoperable pancreatic cancer. There is very little that can be done for these people after they have been treated with first-line therapy. We are going to take these people and use our treatment and compare it to one of the current standards of care for these people, which is not very effective and has toxicity associated with it and see if we can do better for the patients in terms of their quality of life and anti-tumor effectiveness of their treatment and, most importantly, can we shrink their inoperable tumors to where they become operable. If that happens, it is obvious what the overall effect is going to be - you are going to have a significant extension of life. Pancreatic cancer is one of the deadliest forms of cancer known to mankind. By 2020 it is going to be the 2nd most-deadly cancer in the world.
Mr. Waggoner: You should mention what happened in the Phase 1/2 trial in terms of that very subject, taking an inoperable tumor to becoming operable!
Dr. Crabtree: There was a Phase I/II trial done back in early 2000s on a small number of patients with pancreatic cancer in Europe. In this trial using fourteen patients, the patients were very sick and had very advanced disease. They each were given our treatment that used the Cell-in-a-Box live cell encapsulation technology plus the prodrug ifosfamide. The capsules were implanted, and then the patients were treated with only two courses of low-dose (one-third of normal) ifosfamide. Remarkable anti-tumor effects were shown. When the results of the trial were compared to historical data for the only treatment available at the time for pancreatic cancer, a cancer drug called gemcitabine, and the only FDA approved treatment, the median survival time for those patients was almost doubled as was the percentage of one-year survivors. Also, the quality of life of the patients was improved over that previously seen with gemcitabine treatment. Most importantly, in three out of the fourteen patients in that study, their tumors were converted from inoperable to operable. If that happens in this new trial and you can surgically remove the tumors, as mentioned previously, the patients should have a meaningful extension of life. Instead of dying in a year or even less, we do not know how long they would live. Getting an inoperable tumor to become operable is a major goal for our work in pancreatic cancer.
We are also using our cancer therapy to develop a treatment for malignant ascites. Nearly all abominable tumors produce a fluid as they grow called ascites fluid. It is usually malignant and I say that because the fluid produced by those tumors can contain live cancer cells. The fluid excreted by those tumors accumulates in the abdomen. The cancer cells in this fluid can seed and form new tumors distant from the original tumor where the ascites fluid came from. A major problem with the ascites fluid is that it can accumulate quite rapidly. It can cause distention of the abdomen. As it accumulates, it is extremely painful for the patient. In fact, it can be so dangerous as to infiltrate the pleural cavity or impinge on the function of the diaphragm such that breathing difficulties and even death can occur. This malignant fluid must be removed on a regular basis, usually once a month or so. It is a painful procedure. Oncologists do not like doing it and certainly the patients do not like doing it, and it is expensive. There is no treatment for it right now other than surgical removal of the fluid every thirty days or so. Dr. Von Hoff, whom I mentioned earlier, had postulated that our treatment for pancreatic cancer may have an effect on the rate of production and accumulation of this ascites fluid. We have been doing preclinical studies for some time in this area. These preclinical studies are continuing. There is a company called Translational Drug Development, which is a Contract Research Organization that specializes in only the oncology area and in preclinical studies and early to mid-phase clinical trials. Dr. Von Hoff is Chief Development officer at Translational Drug Development, or TD2. These studies are ongoing. If we can find that our treatment works to reduce the rate of malignant ascites fluid accumulation, then, we have another avenue to go down.
CEOCFO: Would you tell our readers why they should take an interest in your company?
Mr. Waggoner: We are excited about everything we are doing. We have a lot on our plate. What we are doing is part of a much bigger picture in terms of treating individuals that so desperately do not have very good alternatives and in many cases no alternatives at all for a successful outcome. We believe we are in the midst of making medical history in the way solid tumors are treated. We also believe that we have an opportunity to provide a treatment for malignant ascites, where none has previously existed, and to our knowledge no one is working on. Then, of course, with diabetes we are tackling the largest healthcare problem in the world with our novel platform technology.
Dr. Crabtree: We do have a lot on our plate but things are moving along quite well. I am excited for both pancreatic cancer and diabetes. Personally, diabetes is a major problem for me and I do not like needles and surely do not want to have to be injected with insulin every day. Just think about what the market is for something like that when you consider there are major big pharma companies that make different forms of insulin or different types of treatments using their form of insulin. If our treatment works as well as we think it will, we could get a lot of noise from those big pharma companies.
“We believe we are in the midst of making medical history in the way solid tumors are treated. We also believe that we have an opportunity to provide a treatment for malignant ascites, where none has previously existed, and to our knowledge no one is working on. Then, of course, we are tackling the largest healthcare problem in the world with our novel platform technology.”- Kenneth L. Waggoner, JD, CEO
PharmaCyte (OTCQU:PMCB)
www.pharmacyte.com
Contact:
Kenneth L. Waggoner
917.595.2850
kwaggoner@pharmacyte.com
today/ 01-28-2017/ in full/ #2/ 01-28-2017/ Keeping an Eye on Pharmacyte Biotech Inc (OTCMKTS:PMCB)
By Jermaine Farmer - January 28, 2017
'PharmaCyte Biotech Inc. (PMCB)'
http://oracledispatch.com/2017/01/28/keeping-eye-pharmacyte-biotech-inc-otcmktspmcb/
Pharmacyte Biotech Inc (OTCMKTS:PMCB) is a micro-cap biotech player pushing its way onto the pancreatic cancer treatment scene.
The company was recently featured in a Stock Market Media Group
piece that helps to better define the company’s message.
The basic gist of that message positions
PMCB as an emerging direct competitor with Ely Lilly (LLY)
and its chemotherapy drug, 'gemcitabine.'
PharmaCyte’s alternative is to use its advanced,
inoperable pancreatic cancer therapy,
“which consists of the company’s signature live-cell encapsulation technology, Cell-in-a-Box,
plus low doses of the FDA-approved chemotherapy drug ifosfamide,
in its upcoming clinical trial where it will go head to head with gemcitabine in order to address an unmet medical need.”
Pharmacyte Biotech Inc (OTCMKTS:PMCB) frames itself as a clinical
stage biotechnology company that focuses on developing and commercializing treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology,
known as Cell-in-a-Box.
Its Cell-in-a-Box technology would be used as a platform to treat various types of cancer,
including advanced and inoperable pancreatic cancer, and diabetes.
The company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed
in the body to enable the delivery of cancer-killing drugs at the
source of the cancer.
It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and examining the benefits of the
Cell-in-a-Box technology to develop therapies for cancer-based
upon the constituents of the Cannabis plant.
The company was formerly known as Nuvilex, Inc.
and changed its name to PharmaCyte Biotech, Inc.
in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and
is based in Silver Spring, Maryland.
According to company materials,
“PharmaCyte Biotech is a clinical stage biotechnology company
developing therapies for cancer and diabetes based upon a
proprietary cellulose-based live cell encapsulation technology
known as “Cell-in-a-Box®.” T
his technology will be used as a platform upon which therapies
for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug
into its active or “cancer-killing” form.
These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible.
Once implanted, a chemotherapy drug that is normally activated in
the liver (ifosfamide) is given intravenously at one-third the normal dose.
The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted.
When the ifosfamide comes
in contact with the encapsulated cells they act as an
artificial liver and activate the chemotherapy drug at the source
of the cancer.
This “targeted chemotherapy” has proven effective and safe to use
in past clinical trials and results in no side effects.”
http://www.OracleDispatch.com
I Was Wrong... For Now/ links too/
Briton Ryle Photo By Briton Ryle
also
http://www.marketwatch.com/
also
https://cabotwealth.com/?mqsc=DS3868863&utm_source=WhatCountsEmail&utm_medium=CAB%20ListINVD%20Dedicated%20Segment&utm_campaign=Spotlight-INVD-1-25-17-short
Written Wednesday, January 25, 2017
I don't have a problem admitting when I am wrong. Back on January 4, I was mulling over what President Trump's first actions and their implications would be. After all, stocks have rallied strongly in anticipation of corporate tax cuts. Banks in particular have enjoyed the added catalysts of changes to Dodd-Frank regulations.
So, I wrote:
The first hundred days in office is the time a new president can run wild. The incoming president has won a "mandate from the people" that should allow him to pass his most important pieces of legislation without too much resistance...
So, what will it be for Trump? This is a really important question if we operate on the assumption that he won't get everything he wants. Even in a Republican-controlled Congress, he's going to hit some resistance.
Maybe the fiscal conservatives will balk at the proposed $1 trillion infrastructure spending bill. Maybe it won't be so easy to simply renegotiate trade deals. And maybe trying to renegotiate deals will spark the trade wars that some people are worried about.
I don't know what policies Trump is prioritizing for his first 100 days. I'm pretty sure it won't be a wall on our border with Mexico. And I'm pretty sure it won't be Obamacare, either (I hear the GOP is worried that leaving a few million people without health care might hurt their approval ratings)...
The optimist in me wants to see Trump take office and then embark on a measured campaign to enact the easiest policy proposal he has: corporate tax cuts. I do not see much opposition to cutting corporate taxes. The benefits would be near immediate. And one success might lead him directly to the next.
So, it looks like I am wrong about this. Trump is not talking taxes right now. He's talking about the wall. He is set to restrict immigration. It appears the repeal of at least parts of Obamacare is coming soon. And Trump has pulled America out of the Trans-Pacific Partnership trade deal.
In other words, Trump is not going after the low-hanging policy fruit. He seems set to take on the most difficult of his campaign promises first.
Taking the Hard Way
A couple weeks ago, I was expecting the market to sell off if Trump decided to take the hard way. It seemed to me that if Trump actually does put off tax reform and starts with Obamacare or trade deals, we'd get a sharp sell-off.
In fact, a lot of traders were saying they planned to take profits around Inauguration Day. And that's probably because historically, markets tend to weaken around that time.
Well, Inauguration Day has come and gone. And Trump seems to be taking the hard way. And the Dow is finally taking out that 20k level. So, what's going on?
Well for one, seasonal patterns don't always work — see "sell in May" over the last five years. I also have to point out that this rally is backed by improving fundamentals...
Bank CEOs have been outright bullish on their businesses for the first time in years. GDP estimates are getting revised higher. Inflation is picking up. The Fed is projecting a slow rise for interest rates. Home sales are improving. And most importantly, earnings are improving. There's more, but you get the point...
Economic indicators were already improving during the fourth quarter. But Trump's win really kicked things into overdrive. As we've discussed, the potential for corporate tax cuts is a big deal.
The economy has momentum, which means Trump may well have some time before he has to deliver on taxes.
I Was Wrong... For Now
Briton Ryle Photo By Briton Ryle
Written Wednesday, January 25, 2017
I don't have a problem admitting when I am wrong. Back on January 4, I was mulling over what President Trump's first actions and their implications would be. After all, stocks have rallied strongly in anticipation of corporate tax cuts. Banks in particular have enjoyed the added catalysts of changes to Dodd-Frank regulations.
So, I wrote:
The first hundred days in office is the time a new president can run wild. The incoming president has won a "mandate from the people" that should allow him to pass his most important pieces of legislation without too much resistance...
So, what will it be for Trump? This is a really important question if we operate on the assumption that he won't get everything he wants. Even in a Republican-controlled Congress, he's going to hit some resistance.
Maybe the fiscal conservatives will balk at the proposed $1 trillion infrastructure spending bill. Maybe it won't be so easy to simply renegotiate trade deals. And maybe trying to renegotiate deals will spark the trade wars that some people are worried about.
I don't know what policies Trump is prioritizing for his first 100 days. I'm pretty sure it won't be a wall on our border with Mexico. And I'm pretty sure it won't be Obamacare, either (I hear the GOP is worried that leaving a few million people without health care might hurt their approval ratings)...
The optimist in me wants to see Trump take office and then embark on a measured campaign to enact the easiest policy proposal he has: corporate tax cuts. I do not see much opposition to cutting corporate taxes. The benefits would be near immediate. And one success might lead him directly to the next.
So, it looks like I am wrong about this. Trump is not talking taxes right now. He's talking about the wall. He is set to restrict immigration. It appears the repeal of at least parts of Obamacare is coming soon. And Trump has pulled America out of the Trans-Pacific Partnership trade deal.
In other words, Trump is not going after the low-hanging policy fruit. He seems set to take on the most difficult of his campaign promises first.
Advertisement
Homeless man turns $500 into $978,750 in just five weeks
Jake Studebaker had lost his house... and was living on the streets of Los Angeles.
Things were looking pretty grim for Jake, until one day he was notified that his grandfather left him a $500 inheritance. You won't believe what he did with it...
Jake went into a local brokerage office and turned that $500 into $978,570 — in just five weeks of trading — all thanks to a simple secret he discovered.
The brokers were absolutely stunned. But here's the thing: you can do this, too.
Click here to learn more.
Taking the Hard Way
A couple weeks ago, I was expecting the market to sell off if Trump decided to take the hard way. It seemed to me that if Trump actually does put off tax reform and starts with Obamacare or trade deals, we'd get a sharp sell-off.
In fact, a lot of traders were saying they planned to take profits around Inauguration Day. And that's probably because historically, markets tend to weaken around that time.
Well, Inauguration Day has come and gone. And Trump seems to be taking the hard way. And the Dow is finally taking out that 20k level. So, what's going on?
Well for one, seasonal patterns don't always work — see "sell in May" over the last five years. I also have to point out that this rally is backed by improving fundamentals...
Bank CEOs have been outright bullish on their businesses for the first time in years. GDP estimates are getting revised higher. Inflation is picking up. The Fed is projecting a slow rise for interest rates. Home sales are improving. And most importantly, earnings are improving. There's more, but you get the point...
Economic indicators were already improving during the fourth quarter. But Trump's win really kicked things into overdrive. As we've discussed, the potential for corporate tax cuts is a big deal.
The economy has momentum, which means Trump may well have some time before he has to deliver on taxes.
Advertisement
The Google Profit Loophole
Google stock is pretty pricey... sitting around $700 per share right now.
However, if you know about the profit loophole known as "Internet Royalties," you could actually bank $2,058 per month.
You don’t have to own Google stock either. And you don’t have to sign up for any programs or fill out any forms.
The best part is you can get started for less than $100.
Check out how to get started collecting these "royalties" today.
What Happens After Dow 20k?
In the early weeks of January, the financial media was obsessed with the Dow Industrials Average hitting the 20,000 level. Day after day, the headlines had some version of Dow 20k in them. And the index would get right there and then sell off.
As the financial media tends to do, it got bored with that story. The turnout for the inauguration became the big topic. And then the protests on Saturday dominated the coverage. You gotta love the irony: the minute the media abandoned the story, the Dow took off to the upside.
Yesterday, I told my colleague Christian DeHaemer that the Dow would take out 20k today. I also told my Real Income Trader readers to buy some call options on Alibaba (NYSE: BABA) to take advantage of the imminent surge for stocks:
I don't have any problem being wrong about the market's next move. If you read yesterday's Real Income Trader Weekly #78, you know I said I thought the market was poised for a downside move. (As an aside, you should always read every alert, regardless of which strategy you are using, because I will typically share my thoughts on direction in each alert.)
Of course, I did acknowledge that there is an upside case as well. And it now looks as though the market is choosing the upside. Dow 20k looks imminent, and it will likely move higher from there. Maybe around 300 points. So we're gonna get some Alibaba calls (NYSE: BABA).
Alibaba reported great earnings last night. The CEO has already met with Trump, so it gets the stamp of approval. And finally, options premiums have collapsed post-earnings, so we can get positioned relatively cheaply.
Those Alibaba call have just about doubled in price overnight. And the rule of big round numbers says that the Dow is going to go higher before there is any noticeable selling. Yeah, I told my Real Income Trader readers we might see 20,300 on the Dow, but I might be wrong; we could see a lot more than that. Don't be surprised if the Dow hits 21k over the next couple of weeks.
http://investorplace.com/stock-quotes/tlog-stock-quote/
JUST CHANGE DA SYMBOL
excerpt/ 10 High-Yield Dividend Stocks That Are SOMEHOW Still Bargains
These names were mostly left out of the recent rally, which makes them the better pick for late-comers
http://investorplace.com/
http://investorplace.com/stock-quotes/cvrr-stock-quote/
Jan 24, 2017, 3:34 pm EST | By James Brumley, InvestorPlace Feature Writer
http://investorplace.com/2017/01/10-high-yield-dividend-stocks-still-bargains/?sid=012517IPDI&cp=IPDI&ct=20170125&cc=eletter&en=4822379&cpp=IPDI&enn=4822379&num=01#.WIj0LPkrKM8
http://investorplace.com/category/stock-picks/stocks-to-buy/#.WIj0m_krKM8
http://investorplace.com/2017/01/shark-tank-canadian-stocks-su-gg-pot/#.WIj0-_krKM8
http://investorplace.com/2017/01/shark-tank-canadian-stocks-su-gg-pot/2/#.WIj1PvkrKM8
name among Canadian stocks that desperately needed strong political leadership, it would be Suncor Energy Inc. (USA) (NYSE:SU). SU isn’t just the northern version of Exxon Mobil Corporation (NYSE:XOM) or Chevron Corporation (NYSE:CVX). In terms of total revenue, SU is the biggest company in the entire country. You can bet that they’re looking for a Shark Tank rally.
Of course, Mr. Wonderful would love to give it to them.
http://investorplace.com/2017/01/shark-tank-canadian-stocks-su-gg-pot/3/#.WIj14fkrKM8
” Potash Corporation of Saskatchewan (USA) (NYSE:POT),
Among Canadian stocks and in general, Goldcorp Inc. (USA) (NYSE:GG) is ideologically an awkward investment at this juncture in history.
Let me explain. Donald Trump captivated his core audience by harping on his outsider image. He’s the guy that’s going to “drain the swamp” because he doesn’t have at least a moral conflict of interest.
Gold, and gold miners like GG, likewise are “outsider investments.” People invest in gold for a variety of reasons, but its most ardent supporters believe gold to be a hedge against financial tyranny. GG and its sort are producers of gold, and thus are one of the “good guys.” However, what happens when gold bugs get their candidate of choice into office? Is there still a reason to hedge?
Judging by the Dow Jones Industrial Average’s failure to crack the 20,000 point barrier, the answer is a resounding yes! Gold prices have been surging in recent weeks, and that’s a major tailwind for GG stock. Another point of bullish confirmation is the fact that Goldcorp is one of the strongest Canadian stocks. Although the year is young, GG stock is up an astounding 18%-plus.
Considering the long-term losses that Goldcorp has suffered, a Shark Tank rally would be just what the doctor ordered!
http://investorplace.com/
//////////////////////////////////////////
http://investorplace.com/2017/01/3-best-under-the-radar-trump-stocks-to-buy/2/#.WIj3c_krKM8
Encore Capital Group , Inc. (NASDAQ:ECPG). Marenzi expects Trump to completely eliminate the Consumer Financial Protection Bureau. Last summer, the watchdog group released a new set of rules and regulations specifically related to debt collection. Debt collection is ECPG’s specialty. The new set of rules was enough for Citi to cut its price target for the stock from $31 to $24. In fact, the stock is down 35% in the last three years over concerns about the impact of new regulations.
If Trump eliminates this threat, ECPG stock could have some major upside. Despite the fact that the stock is up more than 55% since Election Day, it still trades at only 7.2 times projected 2017 earnings.
Under-the-Radar Trump Stocks to Buy: US Concrete Inc (USCR)
Under-the-Radar Trump Stocks to Buy: US Concrete Inc (USCR)
If Trump is really going to pump $1 trillion into infrastructure projects, companies that are well-positioned could see major tailwinds. Large-cap construction stocks Vulcan Materials Company (NYSE:VMC) and Caterpillar Inc. (NYSE:CAT) are often mentioned as Trump stocks. However, Hodges Fund portfolio manager Craig Hodges believes small-cap stock US Concrete Inc (NASDAQ:USCR) will also be a big winner.
“U.S. Concrete is concentrated in areas that have population growth that can support long-term demand from housing, as well as infrastructure spending on airports, roads, bridges, and much needed highway investment,” Hodges recently said. He added that there are also plenty of M&A opportunities in the fragmented concrete market.
USCR stock is up 35% since Election Day. Fortunately, it still trades at a reasonable forward price-to-earnings ratio of 17.5 and an attractive price-to-free-cash-flow of only 10.1. Those numbers make USCR stock a much better infrastructure value play than both CAT and VMC.
Under-the-Radar Trump Stocks to Buy: CVR Refining LP (CVRR)
Under-the-Radar Trump Stocks to Buy: CVR Refining LP (CVRR)
CVR Refining LP (NYSE:CVRR) is in the enviable position of potentially benefiting from two different aspects of Trump’s policy goals.
First, Trump has made clear that his energy policy will focus on energy independence. Trump plans to make full use of America’s domestic coal, natural gas and shale oil resources.
Second, Trump’s deregulation agenda could be huge news for CVRR stock. Trump and recently appointed special adviser on business regulations, Carl Icahn, will likely change or eliminate the Renewable Identification Numbers requirement. CVRR stock could instantly see one of its largest costs completely eliminated.
According to Bloomberg, CVRR spent roughly $220 million on meeting RINs requirements in 2016. Incredibly, that cost amounts to roughly 15% of CVRR’s entire market cap.
Icahn, who is a major CVRR investor, penned a scathing critique of the RINs requirement in the Wall Street Journal back in November. Icahn said the RINs market is filled with “manipulation, speculation and fraud.”
CVRR stock is up 66% since Election Day as investors cheer the possibility of an end to RINs. However, there seems to be plenty of upside remaining. CVRR stock is still down down 34.9% from a year ago.
GOLD SILVER/ links
http://www.angelnexus.com/o/web/119059/x
"The Physical Gold Buyer's Guide"
"The Golden Portfolio: Your Ultimate 'Buy List' for the Coming Run-Up to $6,500 an Ounce"
"The 21st Gold Bull Market Supercycle: Seeing the Big Picture"
"The Ultimate Silver Portfolio"
http://www.kitco.com
http://www.wealthdaily.com/
http://www.wealthdaily.com/articles/yukon-gold-20/8478
Investing in Gold with the Tocqueville Gold Fund (TGLDX)
http://www.wealthdaily.com/report/investing-in-junior-mining-stocks/1336
Silver Standard Resources (NASDAQ: SSRI)
B2Gold (NYSE: BTG)
Junior Gold Miners ETF (NYSE: GDXJ)
LITHIUM EXPLORATION GROUP ENGAGES INNOVATION ASSOCIATES FOUNDER ERIC R DIX TO EVALUATE PATENTED LITHIUM IP FOR ACQUISITION
http://ih.advfn.com/p.php?pid=nmona&article=73680928
Date : 01/24/2017 @ 9:25AM
Source : InvestorsHub NewsWire
Stock : Lithium Exploration Group, Inc. (PC) (LEXG)
Quote : 0.0055 0.0016 (41.03%) @ 11:16AM
LITHIUM EXPLORATION GROUP ENGAGES INNOVATION ASSOCIATES FOUNDER ERIC R DIX TO EVALUATE PATENTED LITHIUM IP FOR ACQUISITION
LITHIUM EXPLORATION GROUP ENGAGES INNOVATION ASSOCIATES FOUNDER
ERIC R DIX TO EVALUATE PATENTED LITHIUM IP FOR ACQUISITION
Print
Alert
Lithium Exploration Group Engages Innovation Associates Founder
Eric R Dix to Evaluate Patented Lithium IP for Acquisition
Phoenix, AZ -- January 24, 2017 -- InvestorsHub NewsWire
-- Lithium Exploration Group Inc. (USOTC: LEXG) today announced
engaging Innovation Associates founded by leading advanced battery technology industry expert Eric R. Dix to evaluate a targeted
portfolio of U.S. Patented Lithium Technologies.
The targeted lithium patents are part of a suite of products being evaluated by LEXG in conjunction with a recently announced lithium aggregating entity. In the contemplated contract LEXG would receive
an initial $1.2 million for access to the
Sonic Cavitation Ltd. lithium harvesting technology.
The $1.2 million would just be the beginning of regular income from
the contract providing access to the Sonic Cavitation Ltd. lithium harvesting technology.
LEXG announced on Thursday, January 19, 2017,
a presentation schedule to be published this week detailing the
recently disclosed negotiation anticipated to result in the
$1.2 million contract for access to the
Sonic Cavitation Ltd. lithium harvesting technology.
LEXG expects to publish the presentation before the end of this week.
The pending contract calls for LEXGs strategic engagement with an integrator of various technologies and services that amount to a
turnkey capacity for delivering usable lithium ready for battery production. In addition to explaining in greater depth the contract under negotiation, the presentation will disclose further measures
LEXG is currently undertaking in conjunction with the contract under negotiation.
About Lithium Exploration Group
Lithium Exploration Group is a US-based exploration and development company focused on the acquisition and development potential of
lithium brines and other precious metals that demonstrate high probability for near-term production. Currently the company is
focused testing its SonCav Technology and the acquisition of
oil and gas related assets in Western Canada.
Lithium Exploration Group is traded on the OTC Markets under the symbol LEXG.
Website: http://www.lithiumexplorationgroup.com.
Safe Harbor Statement
This news release contains "forward-looking statements".
Statements in this press release that are not purely historical are forward-looking statements and
include any statements regarding beliefs, plans, expectations or intentions regarding the future testing of the ultrasonic technology.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors.
Such factors include, among others, the inherent uncertainties associated with mineral exploration and difficulties associated
with obtaining financing on acceptable terms. We are not in control
of lithium prices and these could vary to make development uneconomic.
These forward-looking statements are made as of the date of this
news release, and we assume no obligation to update the
forward-looking statements, or to update the reasons why
actual results could differ from those projected in the
forward-looking statements.
Although we believe that the beliefs, plans, expectations and
intentions contained in this press release are reasonable,
there can be no assurance that such beliefs, plans, expectations
or intentions will prove to be accurate. Investors should consult
all of the information set forth herein and should also refer to
the risk factors disclosure outlined in our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Info
Shanon Chilson
480-641-4790
info@lithiumexplorationgroup.com
#6/ Reader,The $11.1 Trillion Trump Retirement Roadmap /////\\\\\
https://pro.agorafinancial.com/TAO_bonanza_0117/LTAOT119/?h=true
http://www.marketwatch.com [-chart]d13p2xj50zkyqm.cloudfront.net/promos_4/AF/TAO/TrumpBonanza_0117/TAO_TrumpBonanza_Testimonial_001.png[/chart]
http://www.bloomberg.com [-chart]d13p2xj50zkyqm.cloudfront.net/promos_4/AF/TAO/TrumpBonanza_0117/TAO_TrumpBonanza_Testimonial_002.png[/chart]
http://www.wealthdaily.com/resources
we’ve been given a gift…
The best gift of them all!
We already know Trump’s game plan.
That means we know WHICH sectors will benefit from his $11.1 trillion tsunami.
And we know that February 6 is the deadline for Trump to submit his budget plan.
That means we also know exactly WHEN they’re set to explode even higher.
the last time we’ve seen anything like this was from 2002 to 2006…
Republicans had control of Congress and the White House…
Just like they have today.
The government reduced banking regulation…
Promoted oil exploration…
And invested billions in infrastructure.
That’s exactly Trump’s roadmap, too.
What do you think is going to happen with tiny stocks that have exposure to these sectors?
Encore Capital.
This tiny financial stock traded at just $0.30 at the time.
And that means you could have started with just a few dollars.
==============================================
iny energy company called Dawson Geophysical.
In June 2003, it was just a $0.17 stock.
Around that time, the government had a $33 billion plan to promote oil and gas exploration.
For big oil companies like Exxon Mobil, $33 billion is nothing.
===============================================
Step #1 and Step #2 into a tiny company called Insteel Industries.
Back in the mid-2000s, it was just an obscure construction company trading for just $0.23.
But as a pure infrastructure play, it was perfectly positioned to explode higher.
When the government started spending hundreds of billions in infrastructure…
============================================
energy company Cheniere
Defense company Applied Energetics
Sterling Construction
Dawson Geophysical
Infrastructure company Insteel Industries
Encore Capital
============================================
Trump has also threatened to dismantle the Dodd-Frank Act, saying it “has made it impossible for bankers to function.”
That’s why Trump will lead to a boom in blockchain technology.
Now, you’ve probably heard of bitcoin – the ultra-popular crypto-currency that burst onto the scene in 2009.
But most folks have absolutely no idea about the secret technology that makes bitcoin transactions so secure…
It’s called blockchain.
==============================================
#1
The United States military is testing blockchain to help secure everything from nuclear weapons to military satellites.
Banks are testing blockchain to manage transactional gridlock occurring inside the $26 billion repo market.
Goldman Sachs recently filed a new blockchain patent in an effort to secure its dominant banking position.
No wonder Business Insider calls it a “$4.2 trillion opportunity” that could “completely overhaul financial services.”
With Trump’s victory, investing in blockchain really became a no-brainer.
==============================================
#2
Forbes called biotech stocks “the great Donald Trump trade.”
And with this penny biotech stock that’s now trading
company is helping develop a new drug for treating cardiovascular diseases.
Early studies indicate the drug could provide superior benefits to Lovaza, which generated nearly $1 billion in annual sales for GlaxoSmithKline.
==================================================
#3
Donald Trump said he would “ask Congress to fully eliminate the defense sequester and submit a new budget to rebuild our military.”
That means we’re going to see massive new military spending.
Now, there aren’t many tiny defensive stocks out there.
next generation of military defense – electronic warfare.
==================================================
#4
Carrier to keep 1,000 jobs in the U.S.
It’s part of his plan to make U.S. manufacturing great again.
And this stock trading for just $0.30 is right in the middle of it.
Similar to Apple, Blackberry and Cisco, who opened up the global smartphone communications market…
This company is building on networking technology leadership and applying it to machines on the shop floor.
======================================
#5
Trump is energy.
He wants to help oil and gas companies by cutting regulation and encouraging more drilling.
As a result, companies with exposure to the energy sector are ready to explode higher.
company that provides service to oil and gas refineries.
#5/ Reader,The $11.1 Trillion Trump Retirement Roadmap /////\\\\\
https://pro.agorafinancial.com/TAO_bonanza_0117/LTAOT119/?h=true
http://www.marketwatch.com [-chart]d13p2xj50zkyqm.cloudfront.net/promos_4/AF/TAO/TrumpBonanza_0117/TAO_TrumpBonanza_Testimonial_001.png[/chart]
http://www.bloomberg.com [-chart]d13p2xj50zkyqm.cloudfront.net/promos_4/AF/TAO/TrumpBonanza_0117/TAO_TrumpBonanza_Testimonial_002.png[/chart]
http://www.wealthdaily.com/resources
you know…
Trump already promised that he’ll “unleash America’s $50 trillion in untapped shale, oil and natural gas reserves.”
So it’s no surprise to anyone that energy spending is about to go through the roof…
Of course, you could make a few bucks buying big, expensive oil companies like Exxon Mobil.
But you won’t get rich… that’s for sure.
look what happened to infrastructure stocks…
Trump is promising to spend $1 trillion in infrastructure.
Now, you could probably throw a dart at these infrastructure plays and have a good chance of hitting a winner.
But it’s unlikely you’ll make a fortune in big companies.
Case in point…
Big infrastructure company Caterpillar jumped only 12.8% in the three weeks following the election.
But here’s where it gets exciting…
[/t]avew[/t]
There’s a tiny construction company called Avew Holdings Inc…
It was “just another” stock trading under $1 before Trump.
//////////////////////////////////////////////////////
Trump promising to repeal Obamacare…
Lots of big health care companies also jumped higher.
But none jumped enough to make you rich.
For example, shares of Pfizer jumped only 4.43%.
But look at what happened with shares of a tiny health care company called United American Health…
Shares turned “great again!”…
Jumping as high as 721% in the two weeks following the election.
#4/ Reader,The $11.1 Trillion Trump Retirement Roadmap /////\\\\\
https://pro.agorafinancial.com/TAO_bonanza_0117/LTAOT119/?h=true
http://www.marketwatch.com [-chart]d13p2xj50zkyqm.cloudfront.net/promos_4/AF/TAO/TrumpBonanza_0117/TAO_TrumpBonanza_Testimonial_001.png[/chart]
http://www.bloomberg.com [-chart]d13p2xj50zkyqm.cloudfront.net/promos_4/AF/TAO/TrumpBonanza_0117/TAO_TrumpBonanza_Testimonial_002.png[/chart]
http://www.wealthdaily.com/resources
Thanks to President Donald Trump…
You could finally make enough money to retire rich.
You just need to take three quick, simple actions…
#1. Ignore everything the insanely biased, left-leaning media is saying about Trump…
#2. Follow what I call “the Trump retirement roadmap” before February 6...
#3. Watch how it is possible to turn a single $100 bill into a $1.5 million fortune in no time!
See, while the lame mainstream media is busy criticizing Trump’s latest tweet…
Something far bigger…
Something way more important…
Is happening right now.
Something that has stunned all the Trump haters.
And something that’s already making a lot of people a ridiculous amount of money...
Trump Will Unleash an $11.1 Trillion
Tsunami in the Markets
See, Trump policies are about to unleash a wave of wealth not seen since Ronald Reagan…
*** An estimated $11.1 trillion in total.
This money will be used to build new roads…
Bridges…
Pull real American oil out of the ground again…
And build working tanks and planes for our military.
Now…
You could make a “yuge” fortune from this.
Take registered Democrat and Trump critic Warren Buffett...
Even though he voted for Hillary…
He made $11 billion in the two weeks following Trump’s election.
Eric G., a Wall Street executive, made an incredible $475,206 in one week.
Billionaire investor Carl Icahn actually left Trump’s victory party in the early morning to bet $1 billion on stocks.
A $1 billion bet!
That’s how confident he is!
But here’s the thing…
You don’t have to be rich to participate in this $11.1 trillion Trump bonanza.
#3/ The $11.1 Trillion Trump Retirement Roadmap /////\\\\\
https://pro.agorafinancial.com/TAO_bonanza_0117/LTAOT119/?h=true
http://www.marketwatch.com [-chart]d13p2xj50zkyqm.cloudfront.net/promos_4/AF/TAO/TrumpBonanza_0117/TAO_TrumpBonanza_Testimonial_001.png[/chart]
http://www.bloomberg.com [-chart]d13p2xj50zkyqm.cloudfront.net/promos_4/AF/TAO/TrumpBonanza_0117/TAO_TrumpBonanza_Testimonial_002.png[/chart]
#2/ http://www.bloomberg.com
http://www.marketwatch.com [-chart]d13p2xj50zkyqm.cloudfront.net/promos_4/AF/TAO/TrumpBonanza_0117/TAO_TrumpBonanza_Testimonial_001.png[/chart]
http://www.bloomberg.com [-chart]d13p2xj50zkyqm.cloudfront.net/promos_4/AF/TAO/TrumpBonanza_0117/TAO_TrumpBonanza_Testimonial_002.png[/chart]
from 2007/ market , s&p , dow30 , commodities , pe ratios are high. 1/3 % could go south.
25yrs. 560% gainer/
super cycle bull,,,8 yrs
inflated by cheap money [that banks are stealing from saving acct's].
no one going to say the truth on high flyers.
safety first
the fed's quit buying bonds
was 800billion now 4.5trillion
gov't continues higher/
10 yrs ago was 8.5 trillion now 20trillion debtor
lehman's went south
weak data
43 million are in poverty
43 million on food stamps
labor force down 63%
GDP UNER 2%
I.M.F. / UTILITY recession proof
peter schiff/dr,doom predicated housing collapse 2007,
robert schiller p/e is at 27 higher than 1987 bear/black monda.
#2/ Pura Naturals, Inc. (PNAT) / interesting product
http://www.thenaturalinvestor.com
book read/
http://thenaturalinvestor.com/pdf/global-war-for-oil.pdf
About the Author
James DiGeorgia is the publisher of several international financial
newsletters.
James is an avid coin collector, and started buying and selling coins
while still in high school. Over the years he’s bought and sold well over
$100 million in rare coins.
After earning a B.A. in economics, James worked as a numismatist
for some of the largest precious metals and numismatic companies in the
world.
In 1991 James accepted the editorship of the world-renowned and
fiercely independent Silver & Gold Report, a precious metals advisory
service. He became known as a tireless advocate of individual investors.
James authored The Insider’s Guide to Buying Gold, Silver and Rare Coins, and
was frequently quoted as an expert in the New York Times, USA Today, Los
Angeles Times, Money magazine, the Chicago Tribune, and Barron’s, to name
just a few.
Since then, James has founded a family of successful financial
newsletters; see its website at http://www.21stcenturyinvestor.com.
James also publishes the Gold & Energ y Advisor (GEA), a monthly
newsletter covering the precious metals, diamond, and energy markets.
As editor, he delivers insightful commentary and investment recommendations,
with the goal of delivering profitable recommendations to subscribers.
The GEA provides news, commentary, and recommendations
that you won’t get elsewhere. Large market-moving forces are
developing that will dramatically affect your investments—but
you won’t hear about them from the mainline media. The GEA is
dedicated to fully informing you about these forces and trends. See
http://www.goldandenergyadvisor.com for more info.
Pura Naturals, Inc. (PNAT) / interesting product
3.41 ? 0.09 (2.71%)
Volume: 1,515,023 @ 4:00:04 PM ET
Bid Ask Day's Range
3.4 3.42 3.35 - 3.56
PNAT Detailed Quote
http://investorshub.advfn.com/Pura-Naturals-Inc-PNAT-31691/
http://www.otcmarkets.com/stock/PNAT/profile
Verified Company Profile 1/13/2017
Contact Info
23101 Lake Center Drive
Suite 100
Lake Forest, CA 92630
Website: http://www.puranaturalsusa.com
Phone: (855) 326-8537
Email: info@puranaturalsproducts.com
Business Description
Pura Naturals, Inc., a Colorado corporation (the "Company") is the parent company of Pura Naturals, Inc.,
a Delaware corporation ("PURA"). PURA was formed in 2013.
The inspiration for the company's creation was the Gulf of Mexico oil spill in 2010. This massive spill released over
200 million gallons of oil along the Gulf Coast,
making it one of the worst oil disasters in history.
The immediate impact on the environment and wildlife was devastating.
PURA partnered with Advanced Innovative Recovery Technology, Inc. (AIRTech), a significant shareholder of PURA,
to create a revolutionary and proprietary bio-based, non-toxic foam called BeBetterFoam(R),
which is made from renewable resources instead of petroleum.
The foam is oileophilic, which means it absorbs grease, grime and oil, but is also hydrophobic,
which means it resists water retention and does not support bacteria. PURA markets and sells a line of cleaning products based on
the BeBetterFoam(R) platform for consumer and commercial use.
PURA products are non-toxic, contain plant-based renewable resources, have a carbon-negative manufacturing footprint,
contain no petroleum by-products, and use no adhesives or glues.
BeBetterFoam (R) is a unique, proprietary polymer process technology that is protected by trade secret,
completely owned by AIRTech and exclusively licensed to PURA,
and is incapable of being reverse engineered.
Less >>
PNAT Security Details
Share Structure
Market Value1 $110,640,089 a/o Jan 13, 2017
Authorized Shares 500,000,000 a/o Dec 30, 2016
Outstanding Shares 33,325,328 a/o Dec 30, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value Not Available
Transfer Agent(s) Verified by Transfer Agent
VStock Transfer LLC
Shareholders
Shareholders of Record Not Available
Security Notes
Capital Change=shs increased by 3.7 for 1 split. Pay date=11/17/2016.
Capital Change=shs increased by 3.7 for 1 split. Pay date=11/17/2016.
Capital Change=shs increased by 3.7 for 1 split. Pay date=11/17/2016.
Capital Change=shs increased by 3.7 for 1 split. Pay date=11/17/2016.
Short Selling Data
Short Interest (%)
Significant Failures to Deliver No
thank you, ah favorite here/ HIRU
Stervc and ALL; MASSIVE updated DD package- $HIRU
Cliff Notes- version of all recent $HIRU DD posts
In an effort to provide one thread that has links to as much DD as possible...please see the following posts and hopefully they serve to provide a better understanding as to the mega potential here at $HIRU.
FACTS--- Nov 2016- Entire Control block was sold to new ownership with no debt, John Zimmerman who then filed an annual list 12/1/16 changing location /situs of company to Colorado and named director.
On 12/8/16- John Zimmerman released a new corporate website http://hirucorp.net that clearly indicates that this company is going MJ.
On 1/4/17- updates to OTC markets website. New CEO appears to have filed all necessary disclosures and filings with OTC markets. . (IMO-then we shall see current status with MJ news this week!)
CRITICAL EMAILS FROM CEO ---
Email #1
HUGE EMAIL FROM CEO - HIRU -BOOM!
From: John zimmerman <hirucorp@gmx.com>
Date: December 30, 2016 at 2:02:33 PM EST
To:
Subject: Re:HIRU Corp
________,
Quote:
I certainly can appreciate your enthusiasm, as well as your cautiousness. As you know the Pink Sheet market is very volatile and can be a mine-field of professional and personal liability. With that being said, I have been advised to give out a very minimal amount of information to shareholders directly, so as much as I want to divulge our great plans, partners and personnel to everyone, I must keep a tight lip and wait for the public press releases to do the talking.
I can say the following:
1-There is definitely no reverse split on the table. I never say never because the nature of business changes, but we don't think we will need it, and I do not want to hurt former shareholders.
2-Currently we are at a little over 1.7 billion outstanding, of which, a little over a half billion is restricted, and should remain so for a while. So we are 1.1 billion outstanding with many shares closely held. Authorized is at 1.8 billion and we see no need to change it anytime soon.
Thank you,
John Zimmerman
CEO/President/Dir
HIRU Corporation
www.hirucorp.net
Hirucorp@gmx.com
Email #2-
Quote:
The first step is to become current with OTCMarkets and we have noticed that they added me to the officers list just in the past day or so, so we are hoping this means they are processing the application.
As soon as that is done information will start coming out and I just ask for everyone's patience although I know its easier said than done. I really want to impress upon everyone that this is not just a little side project for any of us it is our livelihood, so we are going to take it very seriously and move very cautiously.
Thanks again for your support.
Thank you,
John Zimmerman
CEO/President/Dir
HIRU Corporation
www.hirucorp.net
Hirucorp@gmx.com
Below, please find a compilation of importnst DD and CLIFF NOTES from oldest to newest...
DD Dempsey:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127514937
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127563332
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127573586
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127588614
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127629843
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127633637
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127634684
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127634934
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127635180
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127648944
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127649093
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127649354
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127693473
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127693551
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127694072
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127710007
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127732399
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127760417
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127745474
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127774563
STERVC- . Must read excellent DD here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127357714
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127636712
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127705746
NOW FOLLOW ALONG WITH DD DEMPSEY As we discover more about the HIRU shell players and what could be in store here.
DD on new Press Relarions and Investment Relations Adam Weiss
It appears they are updating OTC markets as changes are occurring and it appears that it's still not complete.
Click here to see: http://www.otcmarkets.com/stock/HIRU/profile
The good news, the new CEO/CFO John S. Zimmerman is now listed properly as directors under HIRU. And os is the new celebrity public relations firm our of NYC!
However, clealry OTC markets are still working on the company updates and I'm sure they are still fixing it as apparently NOW- it also still lists the OLD management (6 very old officers (who were Doctors) and long gone) from 2009 as well! It used to only have the old officers listed folks.
Never the new CEO John Zimmerman.
AND NOW THIS.... ADAM WEISS ...newly listed as Head of Public Relations/ IR !
Now, Check out the success of Adam Weiss and his NY PR Firm! AMWPR !!
Here is a link to Adam Weiss folks - MEGA DD --- huge PR firm. http://www.amwpr.com/our-team.html
ADAM WEISS - LinkedIn- https://www.linkedin.com/in/adamweisspr
http://www.amwpr.com/about/
Adam Weiss ---"PR consultant who gets you featured in major newspapers & broadcast TV (CNN,Good Morning America, and Fox News and more"
From his LinkedIn on his firm--- We're there when you need us. We help clients strategize before, during and after crisis situations to ensure your lasting image is a positive one.
Our clients have appeared on Fox News, Fox & Friends, CNN, NY Post, NY Times, ABC, Today Show, Good Morning America and much more .
Our Specialties:
Public Engagement, Public Relations, PR, Digital Communications, Strategic Communications, Marketing, Corporate Relations, Crisis Communications, Public Affairs, Social Media and Integrated Marketing Communications. Government, Politics, Health & Fitness, Technology, Web Start-ups.
Each AMWPR client campaign is tailored to specific client needs, we know every company has different goals and has their own unique audience that will help grow their brand. That's why we start each campaign with an intrinsic approach. Tailoring your account with only implementing services you need so you're not billed for services that aren't to your advantage.
Industry: Advertising & Marketing , Business Services
Company Attributes: Has locations in North America
Company Description: AMWPR is a full service, innovative media communications firm. We have engineered breakthrough publicity for a diverse group of clients including gaining placement on CNN, Good Morning America, Fox News , MSNBC, The Today Show and other major broadcast outlets. As well, our clients have been featured in The New York Times, The New York Post, Forbes, Capitol Business and other major print publications. Our diverse team is experienced in news, politics, marketing, design, sales, social media, advertising and other phases of media.
Why choose "AMWPR" for your company? It takes experience, expertise and innovative thinking to deliver your message in the manner and medium you want. The staff of AMWPR is creative, smart and engaging, with intimate relationships in key media markets and other walks of life. If you need any further reason to give us a call, just look at our results. Our clients have recieved millions of impressions across countless outlets.
THIS IS MASSIVE.....OTC MARKETS UPDATED and now we discover the excellent press relations company in place.
YOU CAN'T PRODUCE MATERIAL EVENTS AND HUGE NEWS and SUCCESSFULLY BRING IT TO MARKET, WITHOUT A PR FIRM IN PLACE!
The best part - THE DISCLOSURES appear to be headed to the public eye as the filings must not be far away, these are now too many catalysts not to realize EXACTLY The potential here. Green rush 2017
MEGA NEW DD -MUST READ on HIRU now for ALL!
IMO, We have already established the likelihood that $HIRU is connected to GRASS ROOTS Medical Clinic - which is actually a MEGA collective of 7 Dispensaries/Medical doctor offices around 5 cities in Colorado. However, Grass Roots is connected to another much larger Colorado Medical Marijuana outfit.....
Please view the Grass Roots Medical clinic : http://www.grassrootsmedical.com/index
adjust to CEGX PXD another link/ http://www.npr.org/sections/thetwo-way/2016/11/16/502337471/usgs-announces-its-largest-oil-and-gas-discovery-ever
[-chart]media.npr.org/assets/img/2016/11/16/161100_midland-basin-map_usgs_custom-697deb603c4ac20a54a7a62db946fe56b5c0a3af-s800-c85.jpg[/chart]
http://www.pxd.com/operations/permian-basin
THE WORLD’S SECOND LARGEST RESOURCE
Permian BasinDiscovering a resource potential of more than 75 billion barrels oil equivalent (BBOE) in the Spraberry/Wolfcamp shales has re-ignited industry activity in the Permian Basin. Production from the Midland Basin, located within the greater Permian Basin, has increased more than 650,000 barrels of oil equivalent per day (BOEPD) since 2009, and horizontal rigs now account for more than 65 percent of all drilling rigs in the area. These findings rank the Spraberry/Wolfcamp as the largest U.S. oil field and as the second-largest oil field in the world.
Pioneer’s production more than doubled from 45 thousand barrels of oil equivalent per day (MBOEPD) in 2011 to 112 MBOEPD in the first quarter of 2015. During that time, we successfully appraised six of the 12 prospective intervals within our extensive acreage position. Several of our wells hold records for highest initial production rates delivered from a specific interval. Even better, production data proves many have a resource potential of more than 1 million barrels of oil equivalent (MMBOE) each.
Pioneer continues to be the largest producer in the Spraberry/Wolfcamp with a resource potential of more than 11 BBOE and an inventory of more than 20,000 untapped horizontal drilling locations.
from ah friend/ T TRADES that transpired SUB PENNY)
T TRADES~ what you should know about them
- used by financial institutions that are non-market makers to
report larger transactions that actually occurred during market hours.
However, since these institutions do not have access to ACT (Automated Confirmation Transaction Service), they use "Form T" to report.
MMs are prohibited from habitual "Off Market” transactions
These ”Off Market” trades are typically used by larger investors
to trade larger lots at pre-arranged prices without risk of driving
the price upward or downward.
Or where two dealers make an arrangement to settle trades between themselves and outside the clearing system.
Just keep in mind that T TRADES can be good or bad. When you can
uncover them in the simplest form, huge gains are to be made.
Follow the money and with Institutional Loading/Buying, so am I.
#2/ Executive Order 11110/ From Wikipedia, the free encyclopedia
Executive Order 11110 was issued by U.S. President John F. Kennedy on June 4, 1963.
https://en.wikipedia.org/wiki/Executive_Order_11110
This executive order amended Executive Order 10289 (dated September 17, 1951)[1] by delegating to the Secretary of the Treasury the president's authority to issue silver certificates under the Thomas Amendment of the Agricultural Adjustment Act, as amended by the Gold Reserve Act. The order allowed the Secretary to issue silver certificates, if any were needed, during the transition period under President Kennedy's plan to eliminate Silver Certificates and use Federal Reserve Notes.
Background[edit]
On November 28, 1961, President Kennedy halted sales of silver by the Treasury Department. Increasing demand for silver as an industrial metal had led to an increase in the market price of silver above the United States government's fixed price. This led to a decline in the government's excess silver reserves by over 80% during 1961. Kennedy also called upon Congress to phase out silver certificates in favor of Federal Reserve notes which, according to the Associated Press at that time, were still backed by gold.[2][3]
Kennedy repeated his calls for Congress to act on several occasions, including his 1963 Economic Report, where he wrote:[4]
I again urge a revision in our silver policy to reflect the status of silver as a metal for which there is an expanding industrial demand. Except for its use in coins, silver serves no useful monetary function.
In 1961, at my direction, sales of silver were suspended by the Secretary of the Treasury. As further steps, I recommend repeal of those Acts that oblige the Treasury to support the price of silver; and repeal of the special 50-percent tax on transfers of interest in silver and authorization for the Federal Reserve System to issue notes in denominations of $1, so as to make possible the gradual withdrawal of silver certificates from circulation and the use of the silver thus released for coinage purposes. I urge the Congress to take prompt action on these recommended changes.
Public Law 88-36[edit]
The House of Representatives took up the president's request early in 1963,[5] and passed HR 5389 on April 10, 1963, by a vote of 251 to 122.[6][7] The Senate passed the bill on May 23, by a vote of 68 to 10.[8][9]
Kennedy signed the bill into law on June 4, 1963 and, on the same day, signed an executive order (11110) authorizing the Treasury Secretary to continue printing silver certificates during the transition period.[10][11] The act, which became Public Law 88-36 (77 Stat. 54), repealed the Silver Purchase Act of 1934 and related laws, repealed a tax on silver transfers, and authorized the Federal Reserve to issue one- and two-dollar bills, in addition to the notes they were already issuing.[12] The Silver Purchase Act had authorized and required the Secretary of the Treasury to buy silver and issue silver certificates. With its repeal, the President needed to delegate to the Treasury Secretary the President's own authority under the Agricultural Adjustment Act.[13]
Text of Executive Order[edit]
President Kennedy's Executive Order (E.O.) 11110 modified the pre-existing Executive Order 10289 issued by U.S. President Harry S. Truman on September 17, 1951, and stated the following:[14]
The Secretary of the Treasury is hereby designated and empowered to perform the following-described functions of the President without the approval, ratification, or other action of the President...
The order then lists tasks (a) through (h) which the Secretary may now do without instruction from the President. None of the powers assigned to the Treasury in E.O. 10289 relate to money or to monetary policy. Kennedy's E.O. 11110 then instructs that:
SECTION 1. Executive Order No. 10289 of September 9, 1951, as amended, is hereby further amended (a) By adding at the end of paragraph 1 thereof the following subparagraph (j):
'(j) The authority vested in the President by paragraph (b) of section 43 of the Act of May 12, 1933, as amended (31 U.S.C. 821(b)), to issue silver certificates against any silver bullion, silver, or standard silver dollars in the Treasury not then held for redemption of an outstanding silver certificates, to prescribe the denominations of such silver certificates, and to coin standard silver dollars and subsidiary silver currency for their redemption,' and (b) By revoking subparagraphs (b) and (c) of paragraph 2 thereof.
SECTION 2. The amendments made by this Order shall not affect any act done, or any right accruing or accrued or any suit or proceeding had or commenced in any civil or criminal cause prior to the date of this Order but all such liabilities shall continue and may be enforced as if said amendments had not been made.
John F. Kennedy,
THE WHITE HOUSE,
June 4, 1963.
Revocation[edit]
The text that had been added to E.O. 10289 by E.O. 11110 remained on the books until President Ronald Reagan issued Executive Order 12608 on September 9, 1987 as part of a general clean-up of executive orders. Executive Order 12608 revoked subparagraph (j) of paragraph 1 of Executive Order 10289, as amended by Executive Order 11110.[15] Thus, E.O. 12608 specifically revoked the relevant portion of E.O. 10289 that had been added by E.O. 11110. This action effectively revoked E.O. 11110. By this time, however, the remaining legislative authority behind E.O. 11110 had been repealed by Congress when Pub.L. 97–258 was passed in 1982.
In March 1964, Secretary of the Treasury C. Douglas Dillon halted redemption of silver certificates for silver dollars. In the 1970s, large numbers of the remaining silver dollars in the mint vaults were sold to the collecting public for collector value. All redemption in silver ceased on June 24, 1968.
JFK Assassination Theory[edit]
See also: John F. Kennedy assassination conspiracy theories § Federal Reserve conspiracy
Jim Marrs, in his book Crossfire, presented the theory that Kennedy was trying to rein in the power of the Federal Reserve, and that forces opposed to such action might have played at least some part in the assassination.[16][17][18] According to Marrs, the issuance of Executive Order 11110 was an effort by Kennedy to transfer power from the Federal Reserve to the United States Department of the Treasury by replacing Federal Reserve Notes with silver certificates.[17] Actor and author Richard Belzer named the responsible parties in this theory as American "billionaires, power brokers, and bankers ... working in tandem with the CIA and other sympathetic agents of the government."[19]
A 2010 article in Research magazine discussing various controversies surrounding the Federal Reserve stated that "the wildest accusation against the Fed is that it was involved in Kennedy's assassination."[17] Critics of the theory note that Kennedy called for and signed legislation phasing out Silver Certificates in favor of Federal Reserve Notes, thereby enhancing the power of the Federal Reserve; and that Executive Order 11110 was a technicality that only delegated existing presidential powers to the Secretary of the Treasury for administrative convenience during a period of transition.[17][18]
5 Month Before Kennedy Assassination He SIgned Executive Order to End Fed -
5 Month Before Kennedy Assassination -
He SIgned Executive Order Getting Rid Of Federal Reserve -
Executive Order 11110 was issued
by U.S. President John F. Kennedy on June 4, 1963 -
https://en.wikipedia.org/wiki/Executive_Order_11110
Donald Trump won the election in a landslide because of bold ideas.
His ideas would erase and remove decades of failed policies
and corrupt agendas that have plagued this country for too long.
As Trump’s transition team continues to fill his cabinet,
more and more attention continues to surround the possible
selections for a variety of high-ranking positions and meetings
that might help decide these appointments. On Monday,
Trump held a meeting with John Allison, the former CEO of the
bank BB&T and of the libertarian think tank the Cato Institute.
We have seen several reports indicating that Trump is considering
Allison for Treasury secretary.
On the campaign trail, Trump often questioned the future of
the Federal Reserve’s political independence.
In line with these comments, Allison wants to
abolish Federal Reserve all together and
go back to the gold standard.
In fact, Allison takes that rhetoric one step further.
While acting as the head of the Cato Institute,
Allison published several thesis indicating that
the Federal Reserve was obsolete and
needed to be abolished as it restricts power
from the people and allows billionaire cronies
to run banks globally.
“I would get rid of the Federal Reserve
because the volatility in the economy
is primarily caused by the Fed,”
Allison wrote in 2014 for the Cato Journal.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127771969
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127683452
- God Bless -
- Amen -
Phoenix TV, One of China's Largest TV Networks, Features Interviews with Medical Marijuana, Inc. CEO Stuart Titus Discussing the Economic Impact of CBD Products
http://finance.yahoo.com/news/phoenix-tv-one-chinas-largest-140000347.html
PR Newswire PR NewswireJanuary 11, 2017
SAN DIEGO, Jan. 11, 2017 /PRNewswire/ -- Medical Marijuana, Inc.
(MJNA) is pleased to announce that the Company's CEO was featured
in a series of interviews on Phoenix TV, one of China's largest TV networks, outlining the history and the various benefits of the Company's products.
The interviews, which were broadcast on Dec. 23 and Dec. 30 of 2016, summarized the personal experiences of
CEO Dr. Stuart Titus and also detailed the disruptive nature and enormous economic potential for Medical Marijuana, Inc.'s cannabidiol (CBD) products.
The broadcast also showcased the Company's major sales subsidiary HempMeds® and flagship product Real Scientific Hemp Oil™ (RSHO™).
The Phoenix TV segments discussed developments such as athletes preferring cannabis to pharmaceutical treatments currently on the
market – and also laid out the vast economic opportunities that CBD products have brought to the ever-expanding cannabis industry.
"If you extrapolate Colorado to California where we have a much
larger population, we believe that this now-legal market is going
to represent about $35 billion,
so this will be the largest cannabis market in the world," Phoenix TV quoted Titus as saying.
"Not only will this add to our national GDP, it's going to improve employment with tremendous job creation."
The interviews were viewable via the Chinese Finance Network,
a program featured on Phoenix TV.
The segments can be viewed HERE and HERE. Phoenix TV currently airs
to an estimated audience of 300 Million people around the globe.
Medical Marijuana, Inc. was the first publicly traded cannabis
company in the United States initially hitting the market in 2009.
For more information for potential investors, please visit the
Investor Relations or Overview page of Medical Marijuana, Inc.'s
website or check out the recent OTC Market Report HERE.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products,
while allowing them to keep their integrity and entrepreneurial spirit.
We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses,
while increasing shareholder value.
For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit http://www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.'s video statement, click here.
hareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
About HempMeds®
HempMeds® is a corporate portfolio company of Medical Marijuana, Inc. (OTC PINK:MJNA) and the Company's exclusive master distributor
and contracted marketing company, handling sales and distribution.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements
and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections.
This material contains statements about expected future events
and/or financial results that are forward-looking in nature and
subject to risks and uncertainties. Such forward-looking statements
by definition involve risks, uncertainties and other factors,
which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not
intended to diagnose, treat or cure any disease.
LEGAL DISCLOSURE
Medical Marijuana Inc. does not sell or distribute any products that
are in violation of the United States Controlled Substances Act (US.CSA).
These companies do grow, sell, and distribute hemp-based products
and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
CONTACT:
Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829- 0070
andrew.hard@cmwmedia.com
http://www.cmwmedia.com
Investor Relations Contact:
EquiNet, LLC
Toll Free: (877) 964.6463
Office/Direct: (858) 264-6500
Email: info@equinet.us
www.equinet.us
pay attention/ ASIAN ARMAGEDDON
http://www.angelnexus.com/o/web/117994
Japan, our closest ally in East Asia,
is under dire threat from China and North Korea.
While the U.S. was distracted by Trump and Clinton,
Japan has been getting ready to take
on its neighbors alone.
ETAH is about as exciting as it gets on the OTCBB; the Company is quickly becoming a leader in developing and commercialization of medical devices. They are currently focusing on a needle-free injection device and pain treatment device.
[-chart]www.microcapdaily.com/wp-content/uploads/2017/01/Comfort-In-device-and-handle.jpg[/chart]
Eternity Healthcare, Inc. (ETAH) is a medical device company based in Canada that specializes in healthcare. They are successful in discovering, developing and marketing new medical devices. ETAH products are manufactured under very strict compliant with ISO 9001:2000 and NF EN ISO 13485:2003 procedures.
ETAH two leading devices are: The Lenis(R) Needle-Free Injection Device, a compact spring loaded pneumatic needle-free hypodermic injection system; and The OMNI rechargeable hand-held treatment device that delivers low-intensity laser simultaneously with a low-frequency electric pulse that provides stimulation treatments.
ETAH flagship product is the Lenis(R) needle free injection device; capable of injecting over 95% of the medicine into the body without ever having to prick the skin with a needle. The device is ideal for people with skin diseases, diabetic patients who inject insulin, kids and other people with fears of needles.
Eternity Healthcare needle free injection device is trade-marked as ‘Comfort-in’. Comfort-in’s application areas include: Diabetes, Pediatric Oncology, Multiple sclerosis, Human growth hormone, Anesthetics, Vaccine, cardiovascular diseases, and Migraine.
Several weeks ago ETAH announced the completion of its Lenis(R), Needle-Free Injection development phase. The Lenis(R) injector underwent rigorous testing, exceeding 1000 individual tests, proving not only reliable but economical. The Lenis(R) Needle-Free Injection system has four major components that each will require individual testing to satisfy regulatory approval. The main component of the system is the injector which uses a high powered spring loaded bursting mechanism.
There is a massive market for the needle free Lenis(R), injector; according to ETAH CEO Hassan Salari “We believe Lenis(R) will revolutionize medical injections as they can now be done without patient fear of needles and with a substantial reduction in cost per injection. The injection systems market is currently estimated at $9.8 Billion for 2016 and expected to grow at 15.5% until reaching $20.17 Billion in size by 2021. Unlike our competition, our design allows for delivery of larger doses, meaning Lenis(R) could be used with traditional needle and syringes used worldwide. We’re confident we have a disruptive technology.”
ETAH also owns the “OMNI TM” is a rechargeable digital hand-held pain treatment device that delivers a low intensity laser simultaneously with a low frequency electric pulse that provides stimulation treatments to effectively relieve muscle pain (analgesic effects), alleviate muscle spasm, improve microcirculation, and enhance immunity functions. The device is designed to be portable and can be used conveniently anywhere. The OMNITMis easy to operate with an easy grip and streamline appearance, suitable for in home use and by professionals.
Eternity Healthcare, Inc.
Hassan Salari
http://www.eternityhealthcare.com
STOCK INFORMATION
SYMBOL: OTCPINK: ETAH
Shares Outstanding: 66,429,868
Market Cap: $11,625,227
[t]#2/ metals/ Gran Colombia Gold dice que ya le cumplió al Hospital de Marmato -
Trillionaire Rothschild Warns His Own $Fiat Central Banking Counter Fitters System Is Failing and Buys Gold -
[-chart]www.gold-eagle.com/sites/default/files/images/ackerman123016-1.jpg[/chart]
Ready For New Year 2017 Massive Rally In Precious Metals And Junior Miners -
http://www.gold-eagle.com/article/ready-new-year-2017-massive-rally-precious-metals-and-junior-miners
Gold Setting Up For A New Year's Surge?
[Suppressed Image]
http://www.gold-eagle.com/article/gold-setting-new-years-surge -
Gold Surges Above $1,150, Mining Stocks Rocket Higher…Time To Buy The Dip -
http://www.gold-eagle.com/article/gold-surges-above-1150-mining-stocks-rocket-higher%E2%80%A6time-buy-dip -
http://www.gold-eagle.com/article/gold-price-significant-rally-begins -
mick to you and your family - Happy New Year -
- God Bless -
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127540138
File Msg | Remove Msg | *Private* Reply
Ignore User
Block NYBob's Private Messages
Follow User
Follow NYBob
In Reply To: this message on the 'DONALD TRUMP AND THE CONSERVATIVE PARTY / DTACP' board
mick Member Profile mick Member Level
Friday, December 30, 2016 4:24:17 PM
Re: NYBob post# 16395
Post #
16398
of 16484 Go
this is bad for americans. permission to kill ????? California DMV licensed 800,000 undocumented immigrants under 2-year-old law
HBRM Herborium Group, Inc. Pink HBRM
Common Stock Alternative Reporting Pink Limited Information
http://www.otcmarkets.com/stock/HBRM/profile
Contact Info
One Bridge Plaza N
Suite 275
Fort Lee, NJ 07024
Website: http://www.herborium.com
Phone: 201-849-4431
Email: InvestorsRelations@herborium.com
Business Description
Herborium Group, Inc., is a novel botanical therapeutics® company focused on developing, licensing, and marketing of proprietary, botanical based medicinal products, targeting unmet medical needs. The Company responds to both consumers and healthcare professionals demand for safe, efficacious, all natural medicinal options for treatment and prevention of selected diseases and health concerns.
HBRM Security Details
Share Structure
Market Value1 $440,589 a/o Jan 06, 2017
Authorized Shares 10,000,000,000 a/o Nov 30, 2015
Outstanding Shares 2,202,945,450 a/o Nov 30, 2015
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value 0.001
Transfer Agent(s)
Colonial Stock Transfer Co., Inc.
Shareholders
Shareholders of Record Not Available
Security Notes
Capital Change=Capital Change=shs decreased by 2 for 3 split. Ex-date=08/03/1998. Rec date=08/03/1998. Pay date=08/03/1998.
Capital Change=shs decreased by 1 for 1000 split. Ex-date=01/27/2014.
Short Selling Data
Short Interest 0 (-100%)
Jul 15, 2015
Significant Failures to Deliver No
and
https://upticknewswire.com/dr-agnes-olszewski-ceo-of-herborium-group-talks-about-their-signature-botanical-treatment-for-acne/
https://upticknewswire.com/category/radio-interviews/
Dr. Agnes Olszewski, CEO of Herborium Group, talks About their Signature Botanical Treatment for AcneJasyn Blair December 12, 2016 Dr. Agnes Olszewski, CEO of Herborium Group, talks About their Signature Botanical Treatment for Acne2016-12-15T11:08:11+00:00 Radio Interviews
Everett Jolly Interviews Dr. Agnes Olszewski, CEO for Herborium Group, Inc. (HBRM), and they discuss their signature product that helps those suffering from acne. --visit for more Interviews and the…
$FDBL Friendable Inc *FDBL Stock: Yet Another Reason To Be Bullish!
$FDBL Market Opportunity
As a whole, mobile applications create a socially connected experience while allowing users to stay active or do as they choose while on the move, pushing forward with both personal and professional goals. Social Networking is one of the fastest growing market segments in mobile communications, continuing to attract new users. A common problem faced across all age and demographic profiles, is the lack of time in each day. Easy, accessible and user driven technologies are replacing traditional avenues of meeting people by providing yet another way to embrace our "Do it all" and "Have it all" mobile - social generation.
"Mobile Devices and The Media Time They Command Is Now Greater Than Desktop and All Other Media Combined" US Statistics Significantly Higher at 51% Mobile vs. 42% Desktop (Source: SmartInsights)
Current Market Size
Mobile - Social "apps" and social media are growing at outstanding rates $76 Billion Market Projected by 2017 (source: Pew Research Center) Over 2 Billion Smart Phones (Mobile Devices) currently shipped annually and the number of Mobile app downloads Worldwide at 102,062m. The projected number of app downloads 2017 to reach 268,692m with $1.5 Trillion in revenue generating transactions from these 2 Billion Devices
partone/ ompany Will Raise $1 Billion To Create Blood Test To Detect Cancer
http://www.forbes.com/sites/matthewherper/2017/01/05/grail-which-aims-to-invent-blood-test-to-detect-cancer-to-raise-1-billion/#2dad75221eb0
Matthew Herper , FORBES STAFF
I cover science and medicine, and believe this is biology's century.
Grail, a San Francisco startup that aims to invent a blood test that can detect cancer early, announced this afternoon that it plans to raise $1 billion in venture capital in its second financing round, a sum that puts the biotech startup in a class with tech names like Uber, Facebook and AirBnb.
As part of the announcement, Grail is also spinning out of its parent company, San Diego’s Illumina, the $2.4 billion (sales) firm that makes most of the DNA sequencing machines that scientists and doctors use to study human biology, diagnose rare genetic diseases and pick treatments for cancer patients. Illumina is keeping a 20% stake in Grail.
“We founded Grail a year ago to enable early cancer detection via a blood-based screening test powered by Illumina sequencing technology,” said Jay Flatley, Executive Chairman of Illumina and current Chairman of Grail. “This raise, when completed, will provide Grail the resources to develop its first products and embark on the large-scale trials required to demonstrate the stringent performance requirements of a cancer screening test.”
The spinout is likely to be popular with many of Illumina’s investors. Grail executives have discussed conducting clinical trials involving hundreds of thousands of patients. These would be expensive, and could be a drag on Illumina’s profitablity. Illumina shares fell 23% last year.
In a press release, Grail said it has received “indications of interest” from investors who would commit $1 billion. That means the money has not been received, and that the size of the funding round could grow. Grail said in an interview that the announcement was made now so Illumina could give clearer guidance to its investors, and because there may be others interested in investing.
part two/ reading/ Company Will Raise $1 Billion To Create Blood Test To Detect Cancer
http://www.forbes.com/sites/matthewherper/2017/01/05/grail-which-aims-to-invent-blood-test-to-detect-cancer-to-raise-1-billion/#2dad75221eb0
The $1 billion round represents a victory–and a gamble — for ARCH venture capitalist Robert Nelsen, who has been pushing venture investments in biotechnology into the nosebleed realms favored by the Silicon Valley set. Traditionally, biotech companies have limited capital, raising first tens then hundreds of millions as drugs progress. Nelsen has recently engineered much bigger deals with Juno Therapeutics (cancer, $120 million raised in its first round in 2013) and Denali Therapeutics (Alzheimer’s and Parkinson’s, $217 million raised in a round in 2015). Those deals, however, would be dwarfed by this one.
Grail was created as a unit of Illumina in late 2015, based on internal research at Illumina that showed sequencing DNA in the bloodstream again and again made it possible to pick up floating bits of DNA from cancer cells much more accurately than scientists previously believed. This data has not been published. At the time, investors including ARCH Venture Partners, Jeff Bezos and Bill Gates invested $100 million in the company.
As chief executive, Illumina hired Jeff Huber, a former Google executive. He says he was inspired to take the job in part by the death of his wife Laura, a healthy 46-year-old, from colorectal cancer. “It’s very mission-driven for me,” he said in an interview this afternoon.
Huber says the company had made progress toward its audacious goal: “A test that will detect all of the major cancer types.” That will require what he calls “ultra-intense genome sequencing and two or three orders of magnitude deeper than anyone else is doing.”
“Cancer is not one thing,” says Huber. “It is really driven by mutations. Every case of cancer is unique. It is a snowflake. Being able to [find it] with medical and statistical rigor drives clinical studies of unprecedented scale.” Already Grail has announced that it has started a 10,000-patient clinical trial, but Huber says studies involving hundreds of thousands of patients will be required, as will machine-learning technologies that the company is in the midst of building up.
The history of creating diagnostic tests in cancer is long and bitter and pockmarked with failure. For existing tests, like PSA for prostate cancer or mammography for breast cancer, debates rage about whether or not the tests harm more patients with additional surgeries and test procedures than they help. For many doctors, Grail’s vision conjures up a whole population of people who are warned they have cancer before there is anything they can do. That’s something that the company will have to grapple with even as it also wrestles with a disease that has afflicted people for the entirety of human history.
In fact, looked at another way, $1 billion isn’t that much. Companies including Pfizer and Johnson & Johnson have spent that on individual experimental medicines–investments that sometimes ended up producing mainly financial losses. Huber says that Grail is going to be “prudent” with the money it is about to raise. “It is capital intensive path,” he says.
TetraLogic Pharmaceuticals Corporation Announces Completion of Sale of SMAC Mimetic and HDAC Inhibitor Assets to Medivir AB
Date : 12/29/2016 @ 10:30AM
Source : GlobeNewswire Inc.
Stock : NO^TLOG (TLOG)
Quote : 0.1102 0.0 (0.00%) @ 2:05AM
TetraLogic Pharmaceuticals Corporation Announces Completion of Sale of SMAC Mimetic and HDAC Inhibitor Assets to Medivir AB
http://ih.advfn.com/p.php?pid=nmona&article=73509938
TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) (“TetraLogic” or “Company”) and its wholly-owned subsidiary
TetraLogic Research and Development Corporation (“TDRC”) today announced that they have completed the sale to
Medivir AB (Nasdaq Stockholm:MVIR) (“Medivir”) of their SMAC mimetic program, including their clinical stage asset birinapant,
and their topical HDAC inhibitor, remetinostat (SHAPE), to Medivir (the “Sale”) for a purchase price of (i) $12 million payable in
cash at closing plus (ii) milestone payments of up to $153 million based on the development and commercialization of TetraLogic’s
product candidates by Medivir subject to certain conditions and limitations described in the Asset Purchase Agreement for the Sale
and (iii) additional earn-out payments based on annual net sales of birinapant, subject to certain conditions and limitations described
in the Asset Purchase Agreement for the Sale as follows:
the Company will be entitled to 5% of annual net sales from $0 to $500,000,000;
the Company will be entitled to 7.5% of annual net sales from $500,000,000 to $1,000,000,000; and
the Company will be entitled to 10% of annual net sales above $1,000,000,000.
Medivir also assumed certain assumed liabilities.
The transaction was approved by the holders of TetraLogic’s outstanding convertible debt (the “Senior Notes”) and by a vote of TetraLogic’s stockholders holding a
majority of the shares eligible to vote, at a stockholders’ meeting held on December 29, 2016.
Under its agreement with the holders of Senior Notes, the Company will use the $12 million cash proceedsreceived at closing of the Sale to redeem $12 million
in aggregate principal amount of the Senior Notes then outstanding. The holders of the Senior Notes have also agreed to extend the maturity date of the
Senior Notes to June 15, 2024 and to receive interest payments in additional Senior Notes in lieu of cash.
The Company has voluntarily delisted its Common Stock, from The Nasdaq Global Market and deregistered its Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended.
In connection with the completion of the Sale, Mr. J. Kevin Buchi, Dr. Mary Ann Gray, Mr. Michael Kishbauch, Mr. Paul Schmitt and Dr. Andrew Pecora each resigned
as a member of the Board of Directors of the Company, effective December 30, 2016. The resignation was not a result of any disagreement with the Company on
any matter relating to the Company’s operations, policies or practices. Additionally, effective December 30, 2016, Mr. J. Kevin Buchi resigned as
Chief Executive Officer of the Company, Mr. Richard Sherman resigned as Senior Vice President, Secretary and General Counsel of the Company,
Mr. Patrick Hutchison resigned as Chief Financial Officer and Treasurer of the Company and Dr. Tony Meehan resigned as Chief Operating Officer of the Company.
In connection with their resignation, each officer entered into a settlement and release agreements pursuant to which each received a lump sum settlement in the aggregate
amount previously disclosed in the Company’s Form 8-K filed on November 14, 2016.
Forward-Looking Statements
Some of the statements in this press release and other written and oral statements made from time to time by TetraLogic and its representatives are
“forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. These statements include statements regarding cost savings and other benefits expected to be derived from the delisting and deregistration and the intent
and belief or current expectations of TetraLogic and its management team. Such statements may be identified by the use of words like “anticipate”, “believe”, “estimate”,
“expect”, “intend”, “may”, “plan”, “will”, “should”, “seek”, the negative of these terms or other comparable terminology. Investors are cautioned that any such forward-looking
statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the
forward-looking statements. Investors should read carefully the factors described in the “Risk Factors” section of TetraLogic’s filings with the SEC, including
TetraLogic’s Form 10-K for the year ended December 31, 2015 and the Company’s Form 10-Q for the quarter ended September 30, 2016, for information regarding risk factors that could affect TetraLogic’s results.
The forward-looking statements contained in this press release speak only as of the date of this press release and TetraLogic undertakes no obligation to publicly update any
forward-looking statements to reflect changes in information, events or circumstances after the date of this press release, unless required by law.
CONTACT: Richard L. Sherman General Counsel, TetraLogic Pharmaceuticals Corporation Richard.sherman@tetralogicpharma.com
$TRQ Turquoise Hill Resources: Oyu Tolgoi Expected to Produce 100,000 to 140,000 Ounces of Gold in Concentrates for 2017
Watch for $ASTI #Solar BOUNCE PLAY!
FT: Glencore weighs buying full control of Mutanda copper mine
Glencore (OTCPK:GLCNF, OTCPK:GLNCY)
Glencore (OTCPK:GLCNF, OTCPK:GLNCY) could take full control of the Mutanda copper mine in the Democratic Republic of Congo it jointly owns with billionaire Israeli mining entrepreneur Dan Gertler, Financial Times reports.
[-chart]ih.advfn.com/p.php?pid=staticchart&s=GLNCY&p=0&t=17&showctype=1&width=336&height=190&vol=1&afterhours=1[/chart]
[-chart]ih.advfn.com/p.php?pid=staticchart&s=GLCNF&p=0&t=17&showctype=1&width=336&height=190&vol=1&afterhours=1[/chart]
Mutanda, which produced more than 162K metric tons of copper and 18K metric tons of cobalt in the first nine months of 2016, has been hailed by analysts as one of Glencore’s most attractive copper assets even though it is in a country where anti-government demonstrations have been brutally suppressed in recent months.
Glencore paid $430M three years ago to buy a 14.5% stake in Mutanda from a privately owned company, which increased its holding to 69% with the rest controlled by Gertler.
Quture Selected One of 50 Most Promising Healthcare Solution Providers 2016
http://ih.advfn.com/p.php?pid=nmona&article=73552569
[-chart]ih.advfn.com/p.php?pid=staticchart&s=QUTR&p=0&t=17&showctype=1&width=336&height=190&vol=1&afterhours=1[/chart]
Date : 01/05/2017 @ 2:30PM
Source : InvestorsHub NewsWire
Stock : Quture International, Inc. (PN) (QUTR)
Quote : 0.0024 0.0017 (242.86%) @ 3:55PM
Quture Selected One of 50 Most Promising Healthcare Solution Providers 2016
Print
Alert
Quture's Product to Become New Universal Platform for Optimal Performance and Outcomes to Transform Payment & Delivery Systems
DAYTONA BEACH, FL--( NewMediaWire ) -
Quture International, Inc. (OTC PINK: QUTR), the proven and experienced clinical performance and outcome analytics and solutions company in American healthcare,
now with global capability,
today announced the significance of being recognized as one of
among the top 50 healthcare solution providers of 2016 by CIO Review.
For further information on this distinction, see Quture's Facebook post at:
https://www.facebook.com/QutureInt/.
Quture's Health Data Science Technology crosses the boundaries of
all customer segments on the
QualOptima Informatics Platform and even within the provider segment
to unify health and healthcare analytics in the market of at least
$24 billion in 2016, estimated to increase to $55 billion by 2021.
Quture's steady progression in 2016 included transformation of QualOptima's medical errors prevention incorporating the
Human Factors Analysis & Classification System (HFACS).
The exponential improvement in QualOptima's Causation Analysis, Classification and Interventions System will transform quality and
risk management (including adverse event investigation and
medical error interventions).
These dramatic advances and completion of the personalized and
precision health technologies and intellectual property of Quture are recognized by CIO Review.
Quture was notified that based on an analysis of over 800 companies providing solutions for the healthcare industry by CIO Review's editorial research team,
Quture was selected based on merit to be part of this annual Healthcare Technology edition.
"It's a great honor to select Quture as one of the 50 Most Promising Healthcare Solution Providers 2016,"
said Jeevan George, Managing Editor of CIO Review.
"Quture's QualOptima Connectivity & Analytics System empowers data-driven decisions to improve health and healthcare while reducing costs."
Quture has carved its niche through vast experience in reviewing
the clinical performance and outcomes of hundreds of healthcare organizations,
by thousands of physicians, for hundreds of thousands of patients.
Its QualOptima informatics platform embeds the technology Quture invented and engineered to empower providers,
payers and patients ("P3") for data-driven decisions ("D3") to achieve optimal wellness and health care.
Quture's P3D3© PaaS informatics platform is the complete solution
to transform the fundamental payment, delivery (medical), quality, analytics,
health and scientific models that are the basis of health care.
By anticipating value-driven outcomes for payment,
Quture has become the most promising informatics system for value-based, optimal clinical, operational and financial outcomes.
"Our long-term product development strategies have come to fruition
and now recognition as a top 50 healthcare solution provider,"
said Landon Feazell, Quture's Chairman & CEO. "
We continue to believe, now more than ever, that our QualOptima informatics platform is the free-enterprise solution to the health
and health care crises in America. We will be marketing and
selling into another 2-3 years of uncertainty, perhaps chaos,
emerging from what has been eight-plus years of wrangling over
insurance coverage, access to health care,
cost and quality at the federal and state levels.
Quture is strategically positioned in each customer segment for the essential financial and market drivers across this spectrum of urgent needs."
The Company's strategies focusing on people for wellness and
as patients for disease interception or management will become clear in 2017.
Quture's P3D3© PaaS informatics platform is the complete solution
to the challenges facing health and health care,
both nationally and globally.
Quture's technology and informatics systems provide solutions cross
the boundaries of traditional customer segments,
our P3, who will find themselves more isolated in the healthcare ecosystem uncertainty and urgently needing our D3 complete solution.
Quture's health care provider and insurer customers will come from
those committed to urgent solutions that will determine their
future to thrive from value-driven outcomes.
Our pharma, medical device and mobile apps,
as well as omics customers will be committed to digital and
precision health. People, whether patients or
seeking optimal health and wellness, will seek to be empowered in those endeavors.
Quture further intends and has undertaken new expertise to file our financial information.
Feazell concluded:
"I believe that positioning our Company and product forecast a most favorable 2017 for Quture.
We intend to complete negotiations begun last year that will confirm this forecast in our most immediate areas of focus.
And we also look forward to reporting our financials with expertise retained and working with us.
With our health, quality of life and, in fact the American economy
at stake, Quture has demonstrated the same commitments as our
customers as we now look forward to 2017."
About CIO Review:
Published from Fremont, California, CIO Review is a print magazine
that explores and understands the plethora of ways adopted by firms
to execute the smooth functioning of their businesses.
A distinguished panel comprising of CEOs, CIOs,
IT VPs including CIO Review editorial board finalized the
"50 Most Promising Healthcare Solution Providers 2016" and
shortlisted the best vendors and consultants. For more info, visit: http://www.cioreview.com.
About Quture International, Inc.
Quture International (OTC PINK: QUTR) is the proven and experienced clinical performance and outcome analytics and solutions company in American healthcare.
Quture's first-to-market clinical intelligence software is the
complete solution for healthcare providers, payers, employers,
and insurance companies seeking to achieve optimal clinical,
financial and operational outcomes.
Q's QualOptima Connectivity & Analytics System empowers value-driven, patient-centered,
personalized care focused on real-time and predictive patient management and patient safety,
with optimal quality demonstrated by outcomes correlated with resource use, revenue and cost.
As an Application Partner of InterSystems Corporation,
Quture's software operates on their HealthShare strategic technology platform to capture,
integrate, aggregate, and analyze data transformed to knowledge in
its innovative second-generation database.
Quture's core competence and value proposition lies in its embedded evidence-based metrics,
clinical content and analytic algorithms developed from over 35 years of measuring performance in hundreds of hospitals, physician organizations and HMO's.
As the free enterprise solution to improving health and healthcare
while reducing costs,
Quture is positioned through its disruptive technology to become
the foremost global provider of value-based clinical intelligence
and knowledge solutions.
Q is a Nevada corporation based in Daytona Beach, Florida, and trades on the OTC exchange under the symbol "QUTR."
Forward Looking Statements: This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations.
Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including:
our ability to continue as a going concern,
adverse economic changes affecting markets we serve; competition in our markets and industry segments;
our timing and the profitability of entering new markets; greater
than expected costs, customer acceptance of our products or
difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed
from time to time in our public announcements and SEC filings.
Although we believe the expectations reflected in the forward-looking statements are reasonable,
they relate only to events as of the date
on which the statements are made, and our future results,
levels of activity, performance or achievements may not meet these expectations.
We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. There is no assurance that a definitive agreement will be completed.
Contact Information
For Further Information:
Quture International
See Landon's Notes at http://www.quture.com
Connect with Us:
Facebook: & Twitter: QutureInt
Contact: geoffrey@quture.com
0.0001'S/ https://www.barchart.com/stocks/quotes/BRNE/technical-chart
https://www.barchart.com/stocks/quotes/BRNW/technical-chart
https://www.barchart.com/stocks/quotes/BTFL/technical-chart
https://www.barchart.com/stocks/quotes/CGUD/technical-chart
https://www.barchart.com/stocks/quotes/FRZI/technical-chart ------
BRNE BRNW BTFL CGUD FRZI
https://www.barchart.com/stocks/quotes/GFOX/technical-chart
https://www.barchart.com/stocks/quotes/GPNI/technical-chart
https://www.barchart.com/stocks/quotes/GRPS/technical-chart
https://www.barchart.com/stocks/quotes/LGBI/technical-chart
https://www.barchart.com/stocks/quotes/MCGI/technical-chart ------
GFOX GMNI GRPS LGBI MCGI
https://www.barchart.com/stocks/quotes/NNRX/technical-chart
https://www.barchart.com/stocks/quotes/PMCM/technical-chart
https://www.barchart.com/stocks/quotes/PWDY/technical-chart
https://www.barchart.com/stocks/quotes/RLTR/technical-chart
https://www.barchart.com/stocks/quotes/TPNI/technical-chart ------
NNRX PMCM PWDY RLTR TPNI
https://www.barchart.com/stocks/quotes/UAMM/technical-chart
https://www.barchart.com/stocks/quotes/VNTH/technical-chart
https://www.barchart.com/stocks/quotes/WPWR/technical-chart
https://www.barchart.com/stocks/quotes/ISBG/technical-chart ------
UAMM VNTH WPWR ISBG
https://www.barchart.com/stocks/quotes/PMCB/technical-chart
https://www.barchart.com/stocks/quotes/PMCB/technical-chart
https://www.barchart.com/stocks/quotes/PMCB/technical-chart
https://www.barchart.com/stocks/quotes/PMCB/technical-chart
https://www.barchart.com/stocks/quotes/PMCB/technical-chart
http://investorshub.advfn.com/~~~%7D((-imgoingfishing-))*-%3E-22714/
Marijuana Stocks: First Trading Day Of 2017
Jan. 4, 2017 7:37 AM ET|4 comments
http://seekingalpha.com/instablog/3646631-anthony-cataldo/4946894-marijuana-stocks-first-trading-day-2017?uprof=46&isDirectRoadblock=true
Below are the results of the first trading day of 2017,
for N=231 marijuana stocks. I used a web crawler to accumulate these measures, and this is always a problem. I lost n=58 of the N=231.
Still, it provides some crude measure of how the January effect might be shaping up.
There are 75 winners and 49 losers. Stay well and preserve capital.
Ticker
12/30/2016
1/3/2017
Change
Winners
Losers
1
ZYNE
$15.59000
$17.95000
$2.36000
1
2
INSY
$9.20000
$9.86000
$0.66000
1
3
GWPH
$111.75000
$112.38000
$0.63000
1
4
IIPR
$18.19000
$18.70000
$0.51000
1
5
CARA
$9.29000
$9.76000
$0.47000
1
6
CGRW
$1.78000
$2.20000
$0.42000
1
7
CBDS
$5.40000
$5.73000
$0.33000
1
8
AXIM
$8.70000
$8.95000
$0.25000
1
9
PNPL
$2.50000
$2.75000
$0.25000
1
10
MNTR
$1.06000
$1.30000
$0.24000
1
11
ACCA
$1.50000
$1.69000
$0.19000
1
12
PRRE
$0.29400
$0.47500
$0.18100
1
13
TWMJF
$6.82000
$7.00000
$0.18000
1
14
ZDPY
$2.13000
$2.25000
$0.12000
1
15
CIIX
$0.40000
$0.51000
$0.11000
1
16
BUDZ
$0.86000
$0.97000
$0.11000
1
17
ESSI
$2.21000
$2.32000
$0.11000
1
18
HLIX
$8.00000
$8.10000
$0.10000
1
19
MYHI
$0.08000
$0.17500
$0.09500
1
20
SPRWF
$1.08600
$1.18000
$0.09400
1
21
NDEV
$1.21000
$1.30000
$0.09000
1
22
IVITF
$1.05000
$1.12000
$0.07000
1
23
ACBFF
$1.72000
$1.78000
$0.06000
1
24
TECR
$0.49500
$0.54500
$0.05000
1
25
NMUS
$0.30200
$0.35000
$0.04800
1
26
NCAP
$0.13800
$0.16100
$0.02300
1
27
OXIS
$0.09320
$0.11500
$0.02180
1
28
CANL
$0.24000
$0.26000
$0.02000
1
29
MSRT
$1.02990
$1.04990
$0.02000
1
30
REFG
$0.13000
$0.15000
$0.02000
1
31
CNZCF
$0.81000
$0.83000
$0.02000
1
32
CNBX
$0.68000
$0.70000
$0.02000
1
33
AMMJ
$0.91500
$0.93400
$0.01900
1
34
INQD
$0.43310
$0.45000
$0.01690
1
35
CLSH
$0.35000
$0.36000
$0.01000
1
36
TRTC
$0.32000
$0.33000
$0.01000
1
37
PKPH
$0.04000
$0.05000
$0.01000
1
38
IMLFF
$0.17000
$0.18000
$0.01000
1
39
IGC
$0.28000
$0.29000
$0.01000
1
40
VHUB
$0.01140
$0.01750
$0.00610
1
41
EDXC
$0.04700
$0.05250
$0.00550
1
42
MJLB
$0.04500
$0.05000
$0.00500
1
43
CBNT
$0.01600
$0.02000
$0.00400
1
44
OWCP
$0.17600
$0.17990
$0.00390
1
45
RSSFF
$0.08700
$0.09000
$0.00300
1
46
SRNA
$0.20000
$0.20300
$0.00300
1
47
GBHPF
$0.02500
$0.02800
$0.00300
1
48
QEDN
$0.00490
$0.00740
$0.00250
1
49
MDRM
$0.03100
$0.03300
$0.00200
1
50
GLAG
$0.01200
$0.01400
$0.00200
1
51
IGPK
$0.00550
$0.00750
$0.00200
1
52
CBMJ
$0.00580
$0.00770
$0.00190
1
53
FBEC
$0.00980
$0.01160
$0.00180
1
54
GRCU
$0.02860
$0.03020
$0.00160
1
55
HMPQ
$0.02190
$0.02350
$0.00160
1
56
SING
$0.01090
$0.01250
$0.00160
1
57
SGBY
$0.02800
$0.02945
$0.00145
1
58
ACOL
$0.00330
$0.00450
$0.00120
1
59
CAFS
$0.01500
$0.01600
$0.00100
1
60
CBIS
$0.06600
$0.06700
$0.00100
1
61
MCIG
$0.19100
$0.19200
$0.00100
1
62
WDRP
$0.00400
$0.00450
$0.00050
1
63
POTN
$0.00260
$0.00300
$0.00040
1
64
NGMC
$0.00170
$0.00210
$0.00040
1
65
PNTV
$0.01461
$0.01500
$0.00039
1
66
VPOR
$0.00060
$0.00090
$0.00030
1
67
ITNS
$0.00210
$0.00230
$0.00020
1
68
UAMM
$0.00170
$0.00184
$0.00014
1
69
LVVV
$0.00100
$0.00110
$0.00010
1
70
USMJ
$0.00030
$0.00040
$0.00010
1
71
WTII
$0.00060
$0.00070
$0.00010
1
72
BAYP
$0.00010
$0.00020
$0.00010
1
73
USEI
$0.00040
$0.00050
$0.00010
1
74
GRPOF
$0.20990
$0.21000
$0.00010
1
75
ICNM
$0.00010
$0.00015
$0.00005
1
76
OPMZ
$0.00450
$0.00450
$0.00000
77
XXII
$1.09000
$1.09000
$0.00000
78
ATTBF
$0.11050
$0.11050
$0.00000
79
AERO
$4.04000
$4.04000
$0.00000
80
ACGX
$0.00040
$0.00040
$0.00000
81
AFPW
$0.00010
$0.00010
$0.00000
82
ERBB
$0.00230
$0.00230
$0.00000
83
CPMD
$0.40000
$0.40000
$0.00000
84
MJTK
$0.00200
$0.00200
$0.00000
85
CBSC
$2.00000
$2.00000
$0.00000
86
CHUM
$0.03000
$0.03000
$0.00000
87
CBCA
$1.00000
$1.00000
$0.00000
88
CVSI
$0.43000
$0.43000
$0.00000
89
DSCR
$0.00010
$0.00010
$0.00000
90
ESPH
$0.04000
$0.04000
$0.00000
91
EFFI
$0.00300
$0.00300
$0.00000
92
ECIG
$0.07800
$0.07800
$0.00000
93
ENRT
$0.03000
$0.03000
$0.00000
94
FFFC
$0.00010
$0.00010
$0.00000
95
FWDG
$0.00010
$0.00010
$0.00000
96
GEAR
$0.00030
$0.00030
$0.00000
97
GRCV
$0.00010
$0.00010
$0.00000
98
HALB
$0.00140
$0.00140
$0.00000
99
HMKTF
$0.01500
$0.01500
$0.00000
100
IJJP
$0.00040
$0.00040
$0.00000
101
UPOT
$0.04000
$0.04000
$0.00000
102
LATF
$0.00010
$0.00010
$0.00000
103
LXRP
$0.31000
$0.31000
$0.00000
104
LCTC
$7.25000
$7.25000
$0.00000
105
LSCG
$0.04000
$0.04000
$0.00000
106
MDEX
$0.20000
$0.20000
$0.00000
107
MRPHF
$1.04000
$1.04000
$0.00000
108
MJMD
$1.25000
$1.25000
$0.00000
109
MYDX
$0.00300
$0.00300
$0.00000
110
MYEC
$0.00470
$0.00470
$0.00000
111
NTRR
$0.31000
$0.31000
$0.00000
112
NEWC
$0.01660
$0.01660
$0.00000
113
NXTTF
$0.18000
$0.18000
$0.00000
114
NHLE
$0.01200
$0.01200
$0.00000
115
NVGT
$0.00220
$0.00220
$0.00000
116
OSLH
$0.00010
$0.00010
$0.00000
117
PLPL
$0.03000
$0.03000
$0.00000
118
PMCM
$0.00010
$0.00010
$0.00000
119
SNNC
$0.18000
$0.18000
$0.00000
120
SLNX
$0.00010
$0.00010
$0.00000
121
SLTK
$0.51000
$0.51000
$0.00000
122
STEV
$0.02000
$0.02000
$0.00000
123
STWC
$0.42400
$0.42400
$0.00000
124
UNGS
$0.00020
$0.00020
$0.00000
125
AMFE
$0.00808
$0.00803
($0.00005)
1
126
VNTH
$0.00059
$0.00050
($0.00009)
1
127
BLDV
$0.00040
$0.00030
($0.00010)
1
128
DEWM
$0.00200
$0.00190
($0.00010)
1
129
ICBU
$0.00400
$0.00390
($0.00010)
1
130
WCIG
$0.00500
$0.00490
($0.00010)
1
131
DIRV
$0.00100
$0.00080
($0.00020)
1
132
MEDT
$0.00100
$0.00080
($0.00020)
1
133
TAUG
$0.00640
$0.00620
($0.00020)
1
134
ENCC
$0.00570
$0.00550
($0.00020)
1
135
GBHL
$0.00384
$0.00359
($0.00025)
1
136
INCC
$0.00190
$0.00160
($0.00030)
1
137
GTSO
$0.03912
$0.03870
($0.00042)
1
138
SIPC
$0.00600
$0.00550
($0.00050)
1
139
RMHB
$0.04300
$0.04240
($0.00060)
1
140
EAPH
$0.02910
$0.02820
($0.00090)
1
141
CGRA
$0.02200
$0.02100
($0.00100)
1
142
BABL
$0.00600
$0.00500
($0.00100)
1
143
UBQU
$0.01400
$0.01300
($0.00100)
1
144
VAPR
$0.00880
$0.00750
($0.00130)
1
145
RFMK
$0.00950
$0.00790
($0.00160)
1
146
VAPE
$0.01600
$0.01400
($0.00200)
1
147
AGTK
$0.03500
$0.03300
($0.00200)
1
148
BLOZF
$0.61310
$0.61060
($0.00250)
1
149
GRNH
$0.09850
$0.09600
($0.00250)
1
150
BLPG
$0.04000
$0.03700
($0.00300)
1
151
HEMP
$0.03450
$0.03120
($0.00330)
1
152
MCPI
$0.17500
$0.17000
($0.00500)
1
153
MCOA
$0.08100
$0.07500
($0.00600)
1
154
LDSYF
$0.48200
$0.47420
($0.00780)
1
155
THCBF
$0.73500
$0.72720
($0.00780)
1
156
DIGP
$0.19500
$0.18700
($0.00800)
1
157
PMCB
$0.15000
$0.14000
($0.01000)
1
158
GBLX
$0.33000
$0.32000
($0.01000)
1
159
KAYS
$0.26750
$0.25630
($0.01120)
1
160
NSPDF
$0.26700
$0.24000
($0.02700)
1
161
BXNG
$1.78500
$1.75000
($0.03500)
1
162
GRWC
$1.14000
$1.10000
($0.04000)
1
163
GRSO
$0.22500
$0.18000
($0.04500)
1
164
MJNA
$0.20000
$0.15000
($0.05000)
1
165
ETST
$0.46000
$0.40000
($0.06000)
1
166
CNAB
$1.57000
$1.51000
($0.06000)
1
167
CCAN
$0.64500
$0.57000
($0.07500)
1
168
MJNE
$1.00000
$0.92000
($0.08000)
1
169
OGRMF
$2.14900
$2.04400
($0.10500)
1
170
CANN
$3.20000
$3.00000
($0.20000)
1
171
HVST
$4.73100
$4.50000
($0.23100)
1
172
SMG
$95.55000
$94.80000
($0.75000)
1
173
ACAN
$3.65000
$2.78000
($0.87000)
1
TOTALS
$359.67044
$364.96896
$5.29852
75
49
$TRQ Turquoise Hill Resources
Rex Energy sells Utica Warrior South assets to Antero Resources for $30M
Rex Energy (NASDAQ:REXX) +4.4% premarket after Antero Resources (NYSE:AR) agrees to acquire its Ohio Utica assets in the Warrior South Area for $30M.
Rex says the assets, which include 4,100 net acres and 14 gross wells currently producing ~9M cfe/day, are non-core and were not included in its future development plans.
Upon closing of the sale, Rex says it has received approval from its bank lenders to maintain the existing $190M borrowing base under its revolving credit facility.
| 9:03 AM ET
iQiyi Eyes 2017 Listing, Renren Finally Retires
Dec. 23, 2016 10:50 AM ET|9 comments | About: Baidu, Inc. (BIDU), RENN
Doug Young Doug YoungFollow(2,047 followers)
Foreign companies, long only, tech
Send Message|Young's China Business Blog
http://seekingalpha.com/article/4032450-iqiyi-eyes-2017-listing-renren-finally-retires
Bottom line: iQiyi won't make an IPO next year even though Baidu (NASDAQ:BIDU) would like to get the company off its books while Renren's (NYSE:RENN) privatization marks one of the last buyouts for a US-listed Chinese firm from a wave dating back to last year.
iQiyi reportedly eyes 2017 IPO
The year 2016 is winding down as an unmemorable one for Chinese IPOs, thanks to a rocky start that cast a chill over the entire space. That said, the new year could be a bit more lively amid signs that China's securities regulator is opening the gates a bit wider to new offerings. That signal could bode well for offshore listings as well, with word that loss-making online video site iQiyi, controlled by online search leader Baidu, is contemplating such an offering next year.
At the same time, Internet stalwart Renren has finally taken a step that I've predicted for a while now and announced a plan to go private. This announcement also seems quite fitting coming now since the end of the year is an appropriate time to mark the end of life as a public company for Renren, once billed as the Facebook (NASDAQ:FB) of China. Renren's announcement is also likely to be one of the last in a flagging stream of similar buyout offers that peaked more than a year ago for undervalued US-listed Chinese companies.
Let's jump right in with iQiyi, which has been caught between a rock and a hard place for quite some time now. The video site has been a drag on Baidu for a while due to its huge losses, which totaled 2.4 billion yuan ($343 million) last year, CEO Gong Yu told me in an interview in September (English article).
Baidu tried to offload the asset earlier this year, but ended up scrapping the deal after investors complained the sale price was too low. That deal had valued the company at $2.8 billion, though at least one rebellious investor calculated the company should be worth around twice that amount (previous post).
Now media are reporting that Baidu is contemplating an IPO for iQiyi as soon as next year in a deal that would value the company at around $5 billion. (Chinese article). The report is quite vague, which indicates that Baidu probably hasn't even hired an investment bank just yet but is just contemplating the idea.
The reality is that Baidu really wants to get iQiyi off its books since its own profits are already suffering from a scandal involving misleading search results earlier this year. Getting rid of iQiyi would quickly give it a nice boost on the bottom line. The only problem is that iQiyi will still be losing money next year, at least according to what Gong Yu told me just three months ago.
He added that the earliest the company could become profitable would be 2018, and wouldn't comment on an IPO timetable at that time. Such a money-losing company wouldn't be all that attractive to investors, which is why next year seems unlikely for an offering despite this latest report. Of course, the company could do some accounting shuffling to accelerate its drive to profitability, but I really do think a 2017 IPO is unlikely and 2018 is probably the fastest we'll see iQiyi go to market.
Renren Waves Bye-Bye
Next there's Renren, which I write about occasionally more for nostalgia reasons than because anyone really cares about the company. The site billed itself as China's next Facebook when it made its IPO in 2012, generating lots of buzz at that time. But then it quickly lost its status as a leading social networking (SNS) site to the better-run Tencent (OTCPK:TCEHY) (HKEx:700), which has built up an SNS juggernaut with its older QQ and newer WeChat messaging services.
Renren has dabbled in a few businesses since essentially abandoning its original SNS service, and the company now bills itself as operator of both an SNS and Internet finance business. I doubt anyone really cares too much what it does these days, which is why Renren has just announced its management has made an offer to take the company private (company announcement).
No buyout price was given in the announcement, which only says the offer would value Renren at $500 million. The company's shares actually rose 3.6 percent after the announcement came out, giving it a $580 million market value. This particular deal does look a bit complex, as it also involves a spin-off, which perhaps is the reason for the discrepancy. Whatever the case, this is certainly a company that won't be missed by anyone on Wall Street, and its buyout is long overdue.
Disclosure: None
Sogou targeting $4B-$5B IPO/ Tencent Holdings (OTCPK:TCEHY) owns a major stake in Sogou's operation.
Jan. 3, 2017 8:31 AM ET|By: Eric McCaffrey, SA News Editor
Sogou, the third largest search engine in China, is considering floating 10%-12% of its shares in an offering to possibly come at some point this year.
Tencent Holdings (OTCPK:TCEHY) owns a major stake in Sogou's operation.
Sogou explicitly targets Baidu (NASDAQ:BIDU) in remarking on the prospect, claiming eventual replacement of the latter over coming years as it sees users becoming more comfortable with its service.
Now read: iQiyi Eyes 2017 Listing, Renren Finally Retires »
Followers
|
17
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1794
|
Created
|
03/06/15
|
Type
|
Free
|
Moderator mick | |||
Assistants $Pistol Pete$ |
INTELLECTUAL STOCK INVESTOR
FORUM FOR ALL STOCKS:
- NYSE $indu
- NASDAQ $compq
- AMEX
- OTCBB
- PINK SHEETS
- GRAY SHEETS
- FOREIGN EXCHANGES
- General Market Indices Daily and Intra-Day Charts $SPX,$COMPQ,$INDU,SPY,QQQ,DIA,MDY,IWM,GLD,SLY
- $gold
~*~Mining and Metals Du Jour~*~
- http://www.InflationData.com
- http://www.wyattresearch.com/
- http://www.noodls.com/index.asp
- http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#
BRICS currency trying to run u.s.a. into bankruptcy.
B - BRAZIL
R - RUSSIA
I - INDIA
C - CHINA
S - SOUTH AMERICA
MISCELLANEOUS CHAT O.K. HERE
http://www.washingtonpost.com/?nid=top_pb_wplogo&reload=true
US Patent Expirations for Big-Selling Biologics
Clinical / Regulatory / Litigation
nice reads/ http://www.hedgeye.com
http://www.theweedblog.com/details-about-the-newly-introduced-senate-medical-marijuana-bill/
3D Printing Stocks 3DPrintInvestor 3DPrintingStocks.com
The Cannabis Stock Reporthttp://www.goldmanresearch.com/ |
$Pistol Pete$ FEEL SHARP BE SHARP - TRADE SMARTER
*** MICK & FRIENDS STOCK PICKS *** M F S P'S
MICRO CAP DAILY
http://www.microcapdaily.com/micro-cap-insider/
http://www.microcapdaily.com/media-technology/
Best of iHub
Moderator: JAYLIN Assistants: OTCRIDDLER, OTC_Skywalker, Sonic Boom, norcalpsl, Penny Soldier
Network with Cannabis Investors & Entrepreneurs
- See more at: http://ab.typepad.com/the_daily_dab/2015/12/the-daily-dab-a-quick-hit-on-cannabis-stocks-010416.html#sthash.Kx0XCtip.dpuf
FITING THE NICHE By Bounty Man
500 MIL. OUTSTANDING SHARE COMPANIES WORKOUT THE BEST HERE/\
Well Capitalized and Well Managed Companies on OTC that have a great chance To Uplist to Big Boards.
Gems like an Amazon in its beginning days.AMZN
Good Research to find and identify these "GEMS". Watch it Grow.
Some Investors just don't have the Time nor Experience to Research good company's developing in their First Years.
Nevis Capital Corp. (OCEE - ...AS- 981,675,380 , OS - 30,117,112.- 01/31/2015
PLEASE, YOUR POST MUST NOT CONTAIN ANYTHING ABOUT "BASHING" ON ANY I-HUB STOCK BOARD.
[-chart]stockcharts.com/c-sc/sc?r=73376&chart=DIRV,uu[305,a]dacayaci[pb20!b50][dg][ilV25][/chart]
[-chart]stockcharts.com/c-sc/sc?r=73376&chart=BSSP,uu[305,a]dacayaci[pb20!b50][dg][ilV25][/chart]
MASTERS GREENS HERE #board-3665
DISCLAIMER:
• The Board Monitor and The Board Assistants herewith, are not licensed
brokers and assume NO responsibility for the actions,
investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith.
Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
CHICAGO ON ST. PATRICK'S DAY , RIVER TURNS GREEN. MARCH 17, 2015
HALTS & suspensions 2015 1ST 2ND 3RD QTRS.
https://www.sec.gov/litigation/suspensions.shtml
UT SIGNALS/SELLING/MANY
http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=ut
DISCLAIMER:
•The Board Monitor and The Board Assistants herewith, Are not licensed brokers and assume NO Responsibility for the Actions,
Investment decisions, and or Messages Posted on this Forum.
•We do NOT recommend that Anyone Buy or Sell any Securities Posted Herewith.
Any Trade entered into Risks the Possibility of Losing the Funds Invested.
•There are NO Guarantees when Buying or Selling Any Security.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |